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Abstract  
Study objectives 
This is a hospital based study carried out at Kosti teaching hospital from 
March 2006 to 2008, using directly observed treatment short course 
(DOTS), to evaluate the efficacy of intermittent chemotherapy compared 
to the currently  adopted short course therapy.  
Research methodology 
A total of 275 smear positive new cases were enrolled and randomized in 
to two groups, the intermittent group (A) and the daily regimen group 
(B).Follow of relapse rate was done for 18 months after completing 6 
months course of treatment. Data were introduced into SPSS program,  
Pearson Chi square and pair independent sample student T-test for 
comparison. The level of significant (P<0.05). 
Results  
By the end of the fourth, fifth and the sixth month, no patient with 
positive sputum was detected in the two groups. 
 It was found that 31% of X-Ray films were normal. Concerning the 
progress of minimal lesion significantly high percentage improved to 
normal X-Ray 58% in group A and 53 % in group B, whereas 42 % in 
group A and 40 % in group B remained as minimal lesion. The results of 
far advanced lesion revealed that intermittent  regimen improved 16.6%  
of the films to normal and minimal lesion , 8.3 % to moderate lesion , 
33.3 % to moderately advanced lesion and 25 % remained unchanged , 
while in the daily regimen , 21 % improved to normal and minimal 
lesion, 5.2 % to moderate lesion , 27 % to moderately advanced lesion 
and 27.6% remained unchanged . Statistical analysis revealed a 
significant difference between the two groups. 
Group A showed a significant high percentage of complete 
improvement of chest pain, while Group B revealed a significant high 
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percentage of partial improvement of the same symptom . Complete 
disappearance of haemoptysis was detected in the two groups. The 
intermittent regimen is effective in complete disappearance of cough and 
fever and the daily regimen is effective in partial improvement of these 
symptoms. Significant decrease in the means of ESR at 6 month 
compared to the initial results in the two groups .Significant weight gain 
was also detected.  
            Insignificant reduction of the initial Alanine Aminotransferase 
enzyme (ALT) was detected in the two groups. An elevated initial mean 
of Aspartate Aminotransferase (AST) was detected in the two groups 
which was decreased after 2 and 4 months of treatment from 42.8 to 29.7 
and 26.7 in group A and from 37.6 to 28.5 and 27.1 in group B 
respectively. However these differences were statistically insignificant. 
Comparison of the results of initial liver enzymes within the group after 2 
and 4 month study revealed a decreased initial ALT in the two groups. 
In the two regimens significant reduce of the initial AST was observed 
after 2 and 4 months. The percentage of patients with initial elevated 
ALT and AST after 2 and 4 months was not significantly decreased in the 
two groups.     
The intermittent regimen appears to have an advantage over the daily 
when the financial issue and patient satisfaction were considered. 
Ultimately the intermittent regimen reduce about 43 % of the cost of 
drugs consumed in the continuation phase of treatment compared to the 
daily regimen.  
Conclusion                                                                   
Treatment outcome revealed that the cure rate was higher in group A (55 
%) than group B (45.5 %); default was lower in group A (40.6%) than 
group (51%). Death rate was comparable in group A 0.8% and 0.7% in 
group B, No relapse case was detected in the two groups. 
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 اﻟﻤﺴﺘﺨﻠﺺ
  
  اﻟﻬﺪف ﻣﻦ اﻟﺪراﺳﺔ
 ﻓﻰ ﺍﻟﻔﺘﺭﺓ ﻤﻥ ﻤﺎﺭﺱ ﺃﺠﺭﻴﺕ ﺍﻟﺩﺭﺍﺴﺔ ﺒﻤﺴﺘﺸﻔﻰ ﻜﻭﺴﺘﻰ ، ﺃﻜﺒﺭ ﻤﺴﺘﺸﻔﻲ ﻤﺭﺠﻌﻲ ﺒﻭﻻﻴﺔ ﺍﻟﻨﻴل ﺍﻷﺒﻴﺽ
 ﺍﻟﺴل ﺍﻟﺭﺌﻭﻱ ﺝ ﺍﻟﻤﺘﻘﻁﻊ ﻗﺼﻴﺭ ﺍﻷﻤﺩ ﻟﻌﻼﺝ ﻤﺭﺽﻫﺩﻓﺕ ﺍﻟﺩﺭﺍﺴﺔ ﻟﺘﻘﻴﻴﻡ ﻨﻅﺎﻡ ﺍﻟﻌﻼ. 8002 ﺇﻟﻰ ﻤﺎﺭﺱ 6002
ﺩل ﻨﺠﺎﺤﻪ ﻌ ﺍﻷﺸﻌﺔ ﻭﻤﺼﻭﺭﺃﺜﺭﻩ ﻋﻠﻲ  ﻟﻠﻤﺭﺽ ﻭﻗﻴﺎﺱ ﻩ ﻋﻠﻲ ﺍﻟﺒﻜﺘﺭﻴﺎ ﺍﻟﻤﺴﺒﺒﺔﻤﻥ ﻨﺎﺤﻴﺔ ﺍﻟﻔﻌﺎﻟﻴﺔ ﻭﺩﺭﺍﺴﺔ ﺃﺜﺭ
ﻤﻌﺩل ﺘﻬﺩﻑ ﻟﺩﺭﺍﺴﺔ  ﻜﻤﺎ ﻋﻠﻲ ﺍﻟﻜﺒﺩ ،ﺎﻫﺝ، ﺍﻵﺜﺎﺭ ﺍﻟﺠﺎﻨﺒﻴﺔ ﻷﺩﻭﻴﺔ ﻤﺭﺽ ﺍﻟﺴل ﺒﻤﺎ ﻓﻴﻬﺎ ﺃﺜﺎﺭﻭﻤﻌﺩل ﻗﻁﻊ ﺍﻟﻌﻼ
ﺍﻟﻌﻼﺝ ﺍﻟﻴﻭﻤﻲ ﺍﻟﻤﻁﺒﻕ ﻤﻘﺎﺭﻨﺔ ﻤﻊ   ﺍﻟﻤﺘﻘﻁﻊ ﻗﺼﻴﺭ ﺍﻷﻤﺩﻨﻅﺎﻡﺒﺎﻟ ﻤﺩﻯ ﻗﺒﻭل ﺍﻟﻤﺭﻴﺽ ﻟﻨﻅﺎﻡ ﺍﻟﻌﻼﺝ ،ﺃﻻﻨﺘﻜﺎﺴﻪ
 .ﻴﺎﹰﺤﺎﻟ
  
  اﻟﺒﺤﺚ ﻣﻨﻬﺠﻴﺔ
ﻭﺼﻔﻴﻪ ﻟﺘﺼﻨﻴﻑ ﺍﻟﻤﺭﻀﻲ ﺤﺴﺏ ﺍﻟﻔﺌﺔ  ﺃﺠﺭﻴﺕ ﺩﺭﺍﺴﺔ. ﻤﺭﻴﻀﺎﹰ572ﺃﺩﺨل ﻟﻠﺩﺭﺍﺴﺔ ﻋﺩﺩ 
  ﻀﻤﺕﻗﺴﻡ ﺍﻟﻤﺭﺽ ﻟﻤﺠﻤﻭﻋﺘﻴﻥ .ﻴﻥﻤﻘﺎﺭﻨﺔ ﺒﻴﻥ ﺍﻟﻨﻅﺎﻤﻭ ﺍﻟﺘﺩﺨﻴﻥ ﻭ ﺩﺭﺍﺴﺔ  ﺍﻟﻌﻤﺭﻴﺔ،ﺍﻟﺠﻨﺱ
ﻜﻤﺎ % 55 ﺒﻨﺴﺒﺔ  ﺸﻔﺎﺀ ﺘﺎﻤﺎﹰ  ﻤﺭﻴﻀﺎﹰ27 ﻤﺭﻴﻀﺎﹰ ﺸﻔﻰ ﻤﻨﻬﻡ 821( ﺍﻟﻌﻼﺝ ﺍﻟﻤﺘﻘﻁﻊ( )ﺃ) ﺍﻟﻤﺠﻤﻭﻋﺔ 
ﺒﻨﻬﺎﻴﺔ %. 5.54 ﺘﺎﻤﺎﹰ ﺒﻨﺴﺒﺔ  ﻤﺭﻴﻀﺎﹰ ﺸﻔﺎﺀ76 ﻤﺭﻴﻀﺎﹰ ﺸﻔﻲ ﻤﻨﻬﻡ 741( ﺍﻟﻨﻅﺎﻡ ﺍﻟﻴﻭﻤﻲ( )ﺏ)ﻀﻤﺕ ﺍﻟﻤﺠﻤﻭﻋﺔ 
ﺘﻤﺕ ﻤﺘﺎﺒﻌﺔ .ﻓﻲ ﺍﻟﻤﺠﻤﻭﻋﺘﻴﻥ% 001 ﺇﻟﻰ ﺴﻠﺒﻲ ﺒﻨﺴﺒﺔ اﻟﺘﻔѧѧѧѧѧѧѧѧѧѧﺎف  ﺘﺤﻭل  ﺍﻟﺸﻬﺭ ﺍﻟﺭﺍﺒﻊ ﻭﺍﻟﺨﺎﻤﺱ ﻭﺍﻟﺴﺎﺩﺱ ﺘﻡ
ﺩﺍﻡ  ﺒﺎﺴﺘﺨﺘﻡ ﺘﺤﻠﻴل ﺍﻟﺒﻴﺎﻨﺎﺕ  . ﺃﺨﺭﻯ ﻟﺘﻘﺼﻰ ﺤﺎﻻﺕ ﺍﻻﻨﺘﻜﺎﺴﺔﺸﻬﺭﺍ81ﺍﻟﻤﺭﻀﻰ ﺍﻟﺫﻴﻥ ﺃﻜﻤﻠﻭﺍ ﺍﻟﻌﻼﺝ ﻟﻤﺩﺓ 
    .(ﻤﺭ ﺒﻊ ﻜﺎﻱ )ﻭﻗﻭﺭﻨﺕ ﺒﺎﺴﺘﺨﺩﺍﻡ ﺒﺭﻨﺎﻤﺞ (  ﺱ. ﺱ. ﺏ.ﺱ)ﺒﺭﻨﺎﻤﺞ 
  
    
  اﻟﻨﺘﺎﺋﺞ
 ﻭﻜﺎﻨﺕ ﺼﻭﺭﺓ  ﻜﻤﺭﻀﻰ ﺴل ﻋﻼﺠﻬﻡﺘﺸﺨﻴﺼﻬﻡ ﻭﻤﻥ ﺍﻟﻤﺭﻀﻲ ﺘﻡ % 13ﺃﻅﻬﺭﺕ ﺍﻟﺩﺭﺍﺴﺔ ﺃﻥ 
 ﺒﻬﺎ ﺍﻟﺘﻬﺎﺒﺎﺕ ﺼﻐﻴﺭﺓ ﻓﻲ  ﻜﺎﻥﻤﻥ ﺼﻭﺭ ﺍﻷﺸﻌﺔ ﺍﻟﺘﻲ% 85ﺃﻅﻬﺭﺕ ﺍﻟﺩﺭﺍﺴﺔ ﺃﻥ . ﺍﻷﺸﻌﺔ ﻗﺒل ﺍﻟﻌﻼﺝ ﻁﺒﻴﻌﻴﺔ 
ﻜﺎﻨﺕ ( ﺏ)ﺸﻔﻴﺕ ﺘﻤﺎﻤﺎﹰ ﻭﺘﺤﻭﻟﺕ ﺍﻟﺼﻭﺭﺓ ﺇﻟﻲ ﺼﻭﺭﺓ ﻁﺒﻴﻌﻴﺔ ﺒﻨﻬﺎﻴﺔ ﺍﻟﻌﻼﺝ، ﺒﻴﻨﻤﺎ ﻓﻲ ﺍﻟﻤﺠﻤﻭﻋﺔ ( ﺃ)ﺍﻟﻤﺠﻤﻭﻋﺔ 
ﻓﻲ ﺍﻟﻤﺠﻤﻭﻋﺔ % 04ﻭ ( ﺃ)ﻤﻥ ﺍﻟﻤﺠﻤﻭﻋﺔ % 24ﺒﻴﻨﻤﺎ ﻟﻡ ﻴﺘﻐﻴﺭ ﺍﻻﻟﺘﻬﺎﺏ ﺍﻟﺼﻐﻴﺭ ﻓﻲ %. 35ﺍﻟﻨﺴﺒﺔ 
ﻤﻘﺎﺒل ( ﺃ) ﻁﺒﻴﻌﻴﺔ ﻓﻲ ﺍﻟﻤﺠﻤﻭﻋﺔ ﻤﻥ ﺼﻭﺭ ﺍﻷﺸﻌﺔ ﺘﺤﻭﻟﺕ ﺇﻟﻲ% 6.61 ﺍﻟﺸﺩﻴﺩ ﺍﻟﻤﺘﻘﺩﻡ ﻟﻼﻟﺘﻬﺎﺏﺒﺎﻟﻨﺴﺒﺔ (.ﺏ)
ﻭ ( ﺃ)ﻤﻥ ﺍﻻﻟﺘﻬﺎﺏ ﺍﻟﺸﺩﻴﺩ ﺍﻟﻤﺘﻘﺩﻡ ﺇﻟﻲ ﺍﻟﺘﻬﺎﺏ ﺼﻐﻴﺭ ﻓﻲ ﺍﻟﻤﺠﻤﻭﻋﺔ % 3.8ﻭﺘﺤﻭﻟﺕ ( ﺏ)ﻟﻠﻤﺠﻤﻭﻋﺔ % 12
ﻓﻲ ﺍﻟﻤﺠﻤﻭﻋﺔ % 6.72  ﻭ(ﺃ)ﺘﺤﻭﻟﺕ ﺇﻟﻲ ﺍﻟﺘﻬﺎﺏ ﻤﺘﻭﺴﻁ ﻓﻲ ﺍﻟﻤﺠﻤﻭﻋﺔ % 3.33، (ﺏ)ﻓﻲ ﺍﻟﻤﺠﻤﻭﻋﺔ % 2.5
( ﺏ)ﻟﻠﻤﺠﻤﻭﻋﺔ % 6.72ل ﻤﻘﺎﺒ( ﺃ)ﻤﻨﻬﺎ ﺇﻟﻲ ﺍﻟﺘﻬﺎﺏ ﻤﺘﻭﺴﻁ ﻤﺘﻘﺩﻡ ﻓﻲ ﺍﻟﻤﺠﻤﻭﻋﺔ % 3.33، ﻜﻤﺎ ﺘﺤﻭﻟﺕ ( ﺏ)
ﻭﻜﺎﻨﺕ ﺍﻟﻔﺭﻭﻗﺎﺕ ﺇﺤﺼﺎﺌﻴﺎﹰ ( ﺏ)ﻟﻠﻤﺠﻤﻭﻋﺔ % 6.72ﻤﻘﺎﺒل ( ﺃ)ﺩﻭﻥ ﺘﻐﻴﺭ ﻓﻲ ﺍﻟﻤﺠﻤﻭﻋﺔ % 52ﺒﻴﻨﻤﺎ ﻅﻠﺕ 
  .ﻤﻌﻨﻭﻴﺔ
ﺃﻅﻬﺭﺕ ﺍﻟﺩﺭﺍﺴﺔ ﺃﻥ ﺍﻟﻨﻅﺎﻡ ﻤﺘﻘﻁﻊ ﻗﺼﻴﺭ ﺍﻷﻤﺩ ﻓﻌﺎل ﻓﻲ ﺍﻟﺸﻔﺎﺀ ﺍﻟﻜﺎﻤل ﻤﻥ ﺍﻟﻜﺤﻪ ﻭﺃﻟﻡ ﺍﻟﺼﺩﺭ، ﺒﻴﻨﻤﺎ 
ﺍﻟﺴﺎﺒﻘﺔ ﻤﻊ ﻭﻀﻊ ﻋﻭﺍﻤل ﺃﺨﺭﻱ ﻓﻲ ﺍﻻﻋﺘﺒﺎﺭ ﻴﻤﻜﻥ ﺍﻟﻨﻅﺎﻡ ﺍﻟﻴﻭﻤﻲ ﻓﻌﺎل ﻓﻲ ﺍﻟﺸﻔﺎﺀ ﺍﻟﺠﺯﺌﻲ ﻟﻨﻔﺱ ﺍﻷﻋﺭﺍﺽ 
IV 
 ﺔ ﺍﻟﺘﺭﺴﻴﺏ ﺍﻻﺒﺘﺩﺍﺌﻲ ﻤﻘﺎﺭﻨﺒﻨﻬﺎﻴﺔ ﺍﻟﻌﻼﺝ ﺤﺩﺙ ﺍﻨﺨﻔﺎﺽ ﻤﻌﻨﻭﻱ ﻓﻲ ﻤﺘﻭﺴﻁ ﻓﺤﺹ.ﺘﺩﺍﺨﻠﻬﺎ ﻻﺨﺘﻔﺎﺀ ﺍﻷﻋﺭﺍﺽ
 . ﺍﻟﻤﺠﻤﻭﻋﺘﻴﻥﻓﻲ ﺯﺍﺩ ﻤﺘﻭﺴﻁ ﺃﻭﺯﺍﻥ ﺍﻟﻤﺭﻀﻲ ﺯﻴﺎﺩﺓ ﻤﻌﻨﻭﻴﺔﻜﻤﺎ . ﺸﻬﻭﺭ 6ﺒﻨﺘﺎﺌﺠﻪ ﺒﻌﺩ 
( ﺃ)ﻤﻥ ﺍﻟﻤﺭﻀﻲ ﻓﻲ ﺍﻟﻤﺠﻤﻭﻋﺔ % 3.78ﺒﺨﺼﻭﺹ ﺭﻀﺎ ﺍﻟﻤﺭﻴﺽ ﻋﻥ ﺍﻟﻨﻅﺎﻡ ﺍﻟﺫﻱ ﻋﻭﻟﺞ ﺒﻪ ﺃﺒﺩﻱ 
ﻋﻥ ﺍﻟﻨﻅﺎﻡ ( ﺏ)ﻤﻥ ﺍﻟﻤﺠﻤﻭﻋﺔ % 8.83 ﺍﻷﻤﺩ، ﺒﻴﻨﻤﺎ ﺃﺒﺩﻱ ﻓﻘﻁﺭﻀﺎﺀﻫﻡ ﺍﻟﺘﺎﻡ ﻋﻥ ﺍﻟﻨﻅﺎﻡ ﺍﻟﻤﺘﻘﻁﻊ ﻗﺼﻴﺭ 
ﺍﻟﻴﻭﻤﻲ ﻭﻫﺫﺍ ﺍﻟﻔﺭﻕ ﺇﺤﺼﺎﺌﻴﺎﹰ ﻤﻌﻨﻭﻱ ﻭﻫﺫﻩ ﻨﺴﺒﺔ ﻤﺘﻭﻗﻌﺔ ﻷﻥ ﺃﺨﺫ ﺍﻟﺩﻭﺍﺀ ﺒﺼﻭﺭﺓ ﻴﻭﻤﻴﺔ ﻋﻤﻠﻴﺔ ﻤﻤﻠﺔ ﻭﻏﻴﺭ ﻤﻁﺎﻗﺔ 
 ﺩﺨلا  ﺤﺒﻭﺏ ﺍﻟﺫﻱ ﺃ ﺒﻌﻘﺎﺭ ﺍﺴﺘﺭﺒﺘﻭﻤﺎﻴﺴﻴﻥ ﺤﻘﻥ ﻤﻘﺎﺒل ﻋﻘﺎﺭ ﺇﻴﺜﺎﻤﺒﻴﺘﻭلﻟﻠﻤﺭﻴﺽ ﻭﻷﻥ ﺒﺩﺍﻴﺔ ﺍﻟﻨﻅﺎﻡ ﺍﻟﻴﻭﻤﻲ ﻴﺒﺩ
  .ﻓﻲ ﺒﺩﺍﻴﺔ ﺍﻟﻨﻅﺎﻡ ﺍﻟﻤﺘﻘﻁﻊ
 ﻤﻊ ﻨﺘﺎﺌﺞ ﻨﻔﺱ ﺍﻹﻨﺯﻴﻤﺎﺕ ﺒﻌﺩ ﺸﻬﺭﻴﻥ TSA ﻭ  TLAﺒﻤﻘﺎﺭﻨﺔ ﺍﻟﻨﺘﺎﺌﺞ ﺍﻷﻭﻟﻴﺔ ﻟﻔﺤﺹ ﺇﻨﺯﻴﻤﺎﺕ ﺍﻟﻜﺒﺩ 
/  ﻭﺤﺩﺓ 1.52ﻟﺘﺭ ﺇﻟﻲ / ﻭﺤﺩﺓ2.82 ﻤﻥ TLA ﺭ ﻤﻥ ﺒﺩﺍﻴﺔ ﺍﻟﻌﻼﺝ ﻭﺠﺩ ﺇﻨﺨﻔﺎﺽ ﻓﻲ ﺍﻟﻤﺘﻭﺴﻁ ﻹﻨﺯﻴﻡ ﺸﻬﻭ4ﻭ 
ﻟﺘﺭ ﻓﻲ / ﻭﺤﺩﺓ6.91ﻟﺘﺭ ﻭ / ﻭﺤﺩﺓ6.12ﻟﺘﺭ ﺇﻟﻲ /  ﻭﺤﺩﺓ5.22، ( ﺃ)ﻟﺘﺭ ﻓﻲ ﺍﻟﻤﺠﻤﻭﻋﺔ / ﻭﺤﺩﺓ12ﻟﺘﺭ ﻭ 
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 اﻟﺨﻼص
 ﻨﺴﺒﺔ ﺍﻟﺸﻔﺎﺀ ﺍﻟﺘﺎﻡ ﻜﺎﻨﺕ ﺃﻋﻠﻲ ﻓﻲ ﺍﻟﻨﻅﺎﻡ ﺍﻟﻤﺘﻘﻁﻊ ﻗﺼﻴﺭ ﺍﻷﻤﺩ  ﻓﻲ ﺃﻥﺴﺔﻴﻤﻜﻥ ﺘﻠﺨﻴﺹ ﻨﺘﺎﺌﺞ ﺍﻟﺩﺭﺍ
 ﺇﺤﺼﺎﺌﻴﺎﹰ ﻤﻌﻨﻭﻴﺔ ، ﺒﺎﻟﺘﺎﻟﻲ ﻨﺴﺒﺔ ﻗﻁﻊ ﺍﻟﻌﻼﺝ ﺃﻗل ﻤﻥ ﺕﻟﻠﻨﻅﺎﻡ ﺍﻟﻴﻭﻤﻲ ، ﻭﻜﺎﻨﺕ ﺍﻟﻔﺭﻭﻗﺎ% 5.54ﻤﻘﺎﺒل % 55
ﻓﻲ ﺍﻟﻨﻅﺎﻡ % 8.0  ﺤﻴﺙ ﺒﻠﻐﺕ، ﻨﺴﺒﺔ ﺍﻟﻭﻓﻴﺎﺕ ﻓﻲ ﺍﻟﻨﻅﺎﻤﻴﻥ ﻤﺘﻘﺎﺭﺒﺔ ﺠﺩﺍﹰ%15ﻤﻘﺎﺒل % 6.04ﺍﻟﻨﻅﺎﻡ ﺍﻟﻴﻭﻤﻲ 
 ﻭﻤﻥ ﻨﺎﺤﻴﺔ ﺍﻗﺘﺼﺎﺩﻴﺔ ﺍﻟﻨﻅﺎﻤﻴﻥﻓﻲ ﺍﻟﻨﻅﺎﻡ ﺍﻟﻴﻭﻤﻲ ﻭﻟﻡ ﺘﻅﻬﺭ ﺍﻟﺩﺭﺍﺴﺔ ﺃﻱ ﺤﺎﻟﺔ ﺍﻨﺘﻜﺎﺴﺔ ﻓﻲ % 7.0 ﻭﻟﻤﺘﻘﻁﻊ ﺍ
 .ﻓﺈﻥ ﺍﻟﻨﻅﺎﻡ ﺍﻟﻤﺘﻘﻁﻊ ﻗﺼﻴﺭ ﺍﻷﻤﺩ ﺃﻗل ﺘﻜﻠﻔﺔ ﻤﻥ ﺍﻟﻨﻅﺎﻡ ﺍﻟﻴﻭﻤﻲ
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 1
1. Introduction 
 
 1.1 Justification                            
 
WHO has been propagating the use of intermittent supervised treatment 
for all cases    including children (Singh V., 2006) further studies are 
required to establish the equivalence of fully intermittent, with the short 
course (Mwandumba; and Squire S.B., 2001). Although antituberculous 
drugs became available worldwide, patient adherence remains a major 
problem, which can be solved by the use of an intermittent regimen 
(Mitcnison D.A., 2004 ). In Japan, the intermittent regimen has a great 
advantage to facilitate directly observed therapy (DOTS) (Wada.M et al., 
2006). 
 Intermittent regimens markedly reduce the manpower required for 
observed therapy and clinical studies  are needed to formulate new 
regimens against the ever-increasing threat of multi - drug resistant TB( 
Brausch L.M., and Bass JB Jr., 1993). Further studies are needed to 
investigate whether high dosage of rifampcin ( R ) (20 mg/kg) will 
increase the bactericidal activity and the speed of sterilization  or not 
(Diacon A.H.  et al., 2007`). 
In Hong Kong, significant number of tuberculous patients failed to stay 
on DOTS, and those who stay initially had better outcomes (Wong M.Y.  
et al., 2005). The treatment of tuberculosis is important both to preserve 
the health of the patient and to prevent the spread of the disease among 
the population (Boldú J et al ., 2007).   
According to Elkheir 2005,the intermittent regimens may be more 
suitable in Sudan. As far as can be ascertained a clinical control trial 
addressing the intermittent chemotherapy has not been conducted in 
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Sudan  therefore, a study  to assess the efficacy of the intermittent 
chemotherapy  and the adverse drug reactions of the antituberculous 
drugs is justifiable and highly needed , Putting in mind the increasing 
incidence rate of T.B in the area of study. 
 
1.2 Global burden of Tuberculosis 
   
         World Health Organization (WHO), which declared tuberculosis a 
global health emergency in 1993(de Souza M.V., 2006)and it remains a 
major cause of mortality in developing countries (Stevenson C.R., et al., 
2007.) 
In Pakistan, Tuberculosis is one of the major illnesses responsible for 
increase in the morbidity and mortality. (Muhan N.  and Darak B. ) , 
remains to be one of the most important infectious diseases worldwide   
(Greinert U. et al ., 2007) and it becomes a common problem in 
developing countries ( P .V .K.et al., 2008 ). The disease  remains a major 
global public health problem ( Stevenson C.R., et al., 2007), It is a major 
health problem In Tanzania according to Kibiki and coworkers 2007, and 
in Timor leste, according to (Martin  and coworkers 2007 and Life-
threatening haemoptysis is a frequent and often fatal complication in 
areas with a high prevalence of tuberculosis (Van den Heuvel M.M. et al., 
2007). 
 
1.3 The epidemiology of Tuberculosis 
 
According to World Health Organization (WHO), Tuberculosis, without a 
coordinated control effort, will infect an estimated 1 billion people by 
2020, killing 70 million ( de Souza M.V., 2006 ). Among the 
communicable diseases, it was considered  the second leading cause of 
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death worldwide, killing nearly 2 million people each year , the World 
Health Organization estimates that  3 million people worldwide who die 
each year due to TB , in addition to 2 billion people have latent TB , the 
rate in the United States  declined  during 1993–2005 ( Manogna 
Maddineni  and Mukta Panda 2008) , in addition to further decrease in 
the rate in 2006 ( CDC 2007 ) . 
According to the Tuberculosis Coalition for Technical Assistance 2007  
(T.B.C.T.A.) , Indonesia  has the third highest global burden of  
tuberculosis in the world , with approximately 2.2 million new cases per 
year , by the end of 2004, Nigeria ranks 4th amongst countries with the 
greatest burden of tuberculosis Kenya ranks tenth in the world annual 
number of tuberculosis cases , the incidence of  tuberculosis has 
significantly increased in the last two decades , Tanzania  ranks 
fourteenth in the world annual number of tuberculosis cases , during the 
two decades, the incidence  increased more than four folds  and Mexico 
had  24255 cases in 2005 , with an estimated incidence rate of 23 cases 
per 100000 people (Taylor O. et al., 2007). In 50 poverty countries, the 
registered  new smear positive cases increased year by year (Liu F.Y., 
2007).In Egypt 20000 people were estimated to be infected  in 2006, 
treatment success rate was 97%, case detection rate was 61% .( Moghazy 
E.E.L., et al.,  ). 
In South Africa 2002. 215120 Tuberculosis patients were registered (Van 
der walt M. et al., 2007). In Australia 2005, a total of 810 cases were 
identified by bacteriological investigations ( Lumb R et al ., 2007 ). Delay 
in diagnosis of smear positive  results in increasing severity, mortality 
and transmission ( sreer amareddy C.T. and Kishore P.V.  2007). Varions 
Types of intermittent chemotherapy regimens have been applied for 
treatment of the disease worldwide (Wada M. et al., 2006). 
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Engaging traditional healers in TB control programs and reducing stigma 
through education could help to reduce patient delays, accelerate 
diagnosis, improve clinical outcomes and reduce disease transmission in 
sub-Saharan Africa ( Cambanis A et al ., 2007 ). The cases were 
increasing in Zimbabwe, other countries in Africa and world-wide 
(Houston S.,et al.,1991). 
In the Sudan 1985, prevalence of TB was estimated by 3% among 
Tigrayan refugees in Eastern Sudan and displaced  native population 
which was two times higher than that found in rural African population  ( 
Zaki 1995). 
  
1.4 Risk factors of Tuberculosis 
1.4.1Tuberculosis and diabetes mellitus (DM) 
According  to Stevenson and coworkers  2007, In developing countries, 
diabetes prevalence is increasing rapidly, it increases the risk of TB and it 
makes a substantial contribution to the burden of incident tuberculosis in 
India. Diabetes accounts for   14.8% of pulmonary tuberculosis and 
20.2% of smear-positive cases. In the past, a relationship between TB and 
diabetes mellitus (DM) was recognized; there is strong evidence for an 
association between them which has potential public health implications. 
Further well-designed studies are needed to assess the magnitude 
precisely . Mortality was higher in diabetics (18%) than controls (6%), 
with death generally occurring within the first 24 hours of hospitalization 
(Touré N.O. et al., 2007). 
In Indonesia, Diabetes mellitus is a known risk factor for tuberculosis, 
and with the increasing prevalence of type 2 Diabetes Mellitus in less 
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developed regions and it seems to have a negative effect on the outcome 
of TB treatment. (Ali jahbana B. et al., 2007). 
Better control of diabetes Mellitus will help to reduce risk of T.B. (Leung 
C.C. et al., 2007). WHO 2006 recommended that Prophylactic pyridoxine 
in the dose of 10mg/day along with Antituberculous treatment , for a 
patient with  Diabetes mellitus , the drug regimen is the same as in non 
diabetic , Strict control of blood glucose is mandatory and doses of oral 
hypoglycemic agents may have to be increased due to interaction with 
rifampcin . 
Accordlng to Ali sjahbana and coworkers  2007, Diabetes Mellitus was 
diagnosed in 14.8% of patients with TB and was associated with older 
age and a greater body weight. On presentation, diabetic patients with TB 
had more symptoms but had no evidence of more-severe TB. After 2 
months, results of sputum microscopic examination were more often 
positive in diabetic patients (18.1% vs. 10.0%). After 6 months, 22.2% of 
cultured sputum specimens.      
 
1.4.2Tuberculosis and socioeconomic factor  
 
In Spain Because of its specific socio-economic conditions and its 
cultural idiosyncrasy, which group frequently generates difficulties with 
respect to complying with the treatment, as well in follow-up and control. 
The treatment of tuberculosis must always be carried out by expert 
doctors (Boldú J. et al., 2007). 
In Poland, socio-economic factors correlated much more closely with a 
final TB diagnosis than subjective disease symptoms ( Romaszko J. et 
al.,). Human Immunosuppressant Virus ( HIV ) is the major cause of the 
increase in TB. Sub-Saharan Africa is endemic for both TB and HIV 
 6
infection.  In northern Tanzania , One-third of patients were TB/HIV co-
infected (Kibiki G.S.  al et., 2007 ).  
In Turkey, other factors found to affect the incidence of TB were having a 
social insurance card and a low annual income (Tanrikulu A.C. et al., 
2008 ). 
In sub-Saharan Africa , it is suggested that  economic development, 
investment in health care and literacy may all be involved in improving 
access to TB services ( Cambanis A. et al ., 2007 ).  
In  Malawi the costs of seeking TB care are high for poor Patients , the 
major challenge is to increase case detection, especially amongst the 
poor, where  it is assumed that  most 'missing cases' are to be found. 
(Simwaka B.N. et al., 2007). Not only this, but also Patient and household 
costs of TB diagnosis are high even where services are provided free of 
charge. In scaling up TB services to reach the Millennium Development 
Goals, there is an urgent need to identify strategies for diagnosing TB that 
are cost-effective for the poor and their households (Kemp JR  et al., 
2007). 
in China the heavy financial burden  on the patients is one of the main 
reasons that some TB patients fail to access and complete treatment. 
Pressure to generate revenue through current incentives in health-care 
financing and poor competence of health workers at the village and 
township levels cause delay and high expenses to TB patients and 
ultimately impede effective TB control ( Liu X. et al .,2007). In 
Philippines patient gain Benefits of free Medical consultation, sputum 
investigation and X Ray which strengthening DOTS (Lofranco V.S. et al., 
2007). To reduce the morbidity impact, in India it was necessary to 
collaborate the governmental efforts with the effect of the 
nongovernmental organization (NGO) partnership (S.B. and Yopadhyay., 
2007) 
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In Lima, Peru, depression and lack of social support were key barriers to 
adherence. Therefore, it is suggested that adherence interventions may be 
of no use unless they target the underlying psychosocial challenges faced 
by patients living with TB and AIDS ( Shin S. et al., 2008 ). In Nepal the 
government and  NGO sector can be complementary in controlling T.B. 
and Government and NGO collaboration in an effective way to improving 
access and quality or come services (Zafor ullh A.N. et al., 2007). 
In Africa. during the 9th Conference of the international union against 
Tuberculosis  and lung diseases ( IUATLD ) for Africa Region , It was  
noted that national TB control programs have taken on a new 
commitment in , since the declaration of TB as a global emergency in the 
1990s , the TB control program package consists of : political will of the 
government and its commitment to support the program , case detection , 
initiation of short course chemotherapy among detected cases ,  ensuring 
the regular supply of essential anti-TB drugs and  establishing a registry 
and reporting system for program monitoring and evaluation (Chaulet P., 
1996).Communication and contact, food, smoking, airborne exposure, 
physical exertion and sexual contact are the main causes of T.B. spread 
(Ahmed F. et al., 2007). Despite 99% DOTS coverage in Bangladesh case 
detection rate still about 70% due to stigmas , fear of T.B. leads people to 
delay in seeking treatment, T.B patients are socially avoided, physically 
isolated even after getting cure from the disease. T.B. stigma also create 
problem in Marriage, and conjugal life, also fear of loosing work prevent 
patients from seeking T.B. health care. The stigmas are more acute and 
make them more vulnerable (Ahmed F. et al., 2007).  
In Khartoum state , 27% of the interviewed women refused to support 
TB-infected relative due to fear of stigmatization (Ali L. et al 
2007),Therefore , TB diagnosis delay is significantly longer in ferades in 
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Nepal, thus it is  important to raise public awareness and to promote 
female autonomy in decision making (Bom T.S. et al., 2007). 
 
1.4.3 Tuberculosis and ethnic diverse 
 
In Golstan province of Iran, the incidence of pulmonary T.B. was 
significantly different among various ethnicities, it was being highest 
among sistanies and this may be due to several factors including 
immigration or even genetic background.The incidence rate among 
sistanies was approximately ten folds of Turks and kurds, six folds of 
Persians, four folds of Turkmen, and 2.5 folds of Afghans of this region 
(Salek S. et al, 2007). In Red sea area of Sudan , smear positive detection 
differs according to ethnic variation ( Zaki 1995).   
 
1.4.4 The impact of Human Immunosuppressant Virus (HIV ) 
epidemic on Tuberculosis  
 
The rising of the HIV epidemic at the beginning of the 1980s has refueled 
tuberculosis spread in Africa and Asia and contributed to the expansion 
of drug-resistant tuberculosis worldwide making the development of new 
drugs and drug regimens for ambulatory treatment a top priority (Salini 
C., 2006 ). Active Tuberculosis is common among HIV- infected patients 
living in T.B. epidemic countries, and screening for T.B. is  
recommended routinely( Bakari M.et al.,) Tuberculosis  was classified as 
an important public health problem worldwide due to AIDS epidemic( de 
Souza M.V., 2006 ). 
In Hong Kong a Considerable TB risk remains after initial contact 
screening. A number of possible risk factors were identified ( Yimer G. et 
al .,2008 ) . The prevalence of HIV is very high among patients with TB 
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in Abuja, Nigeria( Lawson L. et al., 2008 ). In Zimbabwe and other 
countries in Africa and world-wide  , TB treatment and control face new 
difficulties including the impact of the HIV epidemic(Houston S.et 
al.,1991). Directly observed therapy for TB in patients with HIV 
infection is highly effective and associated with better adherence to 
therapy and survival (Alwood K. et al., 1994). 
In Sudan a relatively low proportion of tuberculosis patients also have 
HIV infection. These patients are substantially more likely to die while on 
treatment for their tuberculosis and they need  more comprehensive care 
if their lives are to be prolonged. In addition, every effort is required to 
diminish the transmission of HIV infection to prevent the tragedy  
represented  to the community by HIV ( El-Sony A.I. et al., 2002). Also 
management of the HIV-positive TB case was more costly than that of 
the HIV-negative case  ( Elsony A.I., 2006). 
 
1.5 Directly observed therapy (DOTS) 
  
The World Health Organization's (WHO) directly observed treatment 
short course  strategy consists of health care or community workers who 
directly observe tuberculosis (TB) patients ingest their anti-TB treatment .  
Directly Observed Treatment Short course strategy achieve  87%  success 
rate in the areas where it is  implemented , usually with 5 drugs, lasts for 
6 months and costs about $11 per patient for the course , also it involves 
the establishment of case detection and monitoring systems , in addition 
to the fact that it is ranked by the World Bank as one of the most cost 
effective of all health interventions , the failure to control TB is due not 
so much to a lack of finances as it is to a lack of political will and 
commitment (Wise J., 1998). Directly supervised therapy is an excellent 
option when enough resources are available ( Brausch L.M. and Bass J.B. 
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J.r., 1993).In Italy, an application of directly observed therapy  , 
especially in cases of adequate compliance  allows intermittent two 
or three times a week Principles of therapy for tuberculosis (Ortona 
L. and Antinori A.,1998 ). 
Concerning Asian countries , DOTS in India appears to be a highly 
effective treatment strategy( Sharma S. et al., 2008). In China the 
coverage was 100% in 2004 and 2005, the finding numbers of smear 
positive tuberculosis cases exceeded the project target and the cure of 
new smear positive cases reached 85%. In Uspakistan, Despite the large 
scale introduction of the DOTS programmes within the last 8 years, 
global targets by WHO have not been a achieved (Yuldashev A., 2007). 
In Bangladesh DOTS implement action improved further from 2005 to 
2006. (Ashraful Alam M.D.  et al., 2007). Despite the successful 
implementation of DOTS in Indonesia , the practice of  tuberculosis 
among physicians is variable , the use of sputum  microscopy is often 
neglected  in addition to incorrect prescribing of antituberculous drugs . 
According to the Tuberculosis Coalition for Technical Assistance 2007 
(T.B.C.T.A.), Indonesia met the 85% target for DOTS treatment success ,  
while in Kenya it is only 50% . Of the 40 African countries participating 
in the 9th IUATLD Conference of the Africa Region, 30 have efficient 
programs (Chaulet P., 1996). 
In Burundi, despite long – term use of DOTS strategy, the drug resistance 
levels are higher than the overage for Africa (Sander M. et al., 2006). 
 
1.6   Diagnosis of Tuberculosis 
Sputum investigation 
WHO has strongly recommended sputum smear examination as the 
preferred screening test and suggests examination of 3 deeply coughed 
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out sputum samples - spot sample on day 1, overnight sample and a spot 
sample in the morning on day 2. Recently it has been shown that sputum 
smear positivity is greater than 90% if 5 ml of sputum is used for smear 
diagnosis of pulmonary TB (Joshi J.M. 2006). In Jordan , according to 
(El-Khushman H et al., 2006 ) , Sputum for Alcohol Acid Fast Bacili 
(AAFB ) remains an important, easy and inexpensive measure for TB 
diagnosis.  
Culture of Mycobacterium Tuberculosis is the gold standard for diagnosis 
of TB , Patients with cough >3 weeks duration attending 8 hospitals in 
Abuja, Nigeria were screened with smear microscopy , culture and tested 
for HIV( Lawson L. et al., 2008 ).   
Radiological investigations 
In the United States, chest radiography is often considered a reliable and 
an important investigation for diagnosis of Tuberculosis ( Manogna 
Maddineni  and Mukta Panda 2008). According to Center of Diseases 
Control (CDC) 2008 , the following guide lines are used for evaluation of  
Chest X-Ray Findings that Can Suggest active TB: 
- Infiltrate or consolidation : Opacification of airspaces within the lung 
parenchyma. Consolidation or infiltrate can be dense or patchy and might 
have irregular, ill-defined, or hazy borders.  
- Any cavitary lesion : Lucency (darkened area) within the lung 
parenchyma, with or without irregular margins that might be surrounded 
by an area of airspace consolidation or infiltrates, or by nodular or 
fibrotic (reticular) densities, or both. The walls surrounding the lucent 
area can be thick or thin. Calcification can exist around a cavity.  
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- Nodule with poorly defined margins: Round density within the lung 
parenchyma, also called a tuberculoma. Nodules included in this category 
are those with margins that are indistinct or poorly defined . The 
surrounding haziness can be either subtle or readily apparent and suggests 
coexisting airspace consolidation.  
- Pleural effusion: Presence of a significant amount of fluid within the 
pleural space. This finding must be distinguished from blunting of the 
costophrenic angle, which may or may not represent a small amount of 
fluid within the pleural space (except in children when even minor 
blunting must be considered a finding that can suggest active TB).  
- Hilar or mediastinal lymphadenopathy (bihilar lymphadenopathy) : 
Enlargement of lymph nodes in one or both hila or within the 
mediastinum, with or without associated atelectasis or consolidation.  
- Linear, interstitial disease (in children only) : Prominence of linear, 
interstitial (septal) markings.   
Chest X-Ray Findings that Can Suggest inactive TB:  
- Discrete fibrotic scar or linear opacity : Discrete linear or reticular 
densities within the lung. The edges of these densities should be distinct 
and there should be no suggestion of airspace opacification or haziness 
between or surrounding these densities. Calcification can be present 
within the lesion and then the lesion is called a “fibrocalcific” scar.  
- Discrete nodule(s) without calcification: One or more nodular 
densities with distinct borders and without any surrounding airspace 
opacification. Nodules are generally round or have rounded edges.  
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- Discrete fibrotic scar with volume loss or retraction: Discrete linear 
densities with reduction in the space occupied by the upper lobe.  
Associated signs include upward deviation of the fissure or hilum on the 
corresponding side with asymmetry of the volumes of the two thoracic 
cavities.  
- Discrete nodule(s) with volume loss or retraction: One or more 
nodular densities with distinct borders and no surrounding airspace 
opacification with reduction in the space occupied by the upper lobe. 
Nodules are generally round or have rounded edges.  
- Other: Any other finding suggestive of prior TB, such as upper lobe 
bronchiectasis. Bronchiectasis is bronchial dilation with bronchial wall 
thickening . 
Respiratory specimen cultures should be obtained in TB suspects with a 
normal X-rays (CXR), particularly HIV-infected persons ( Pepper T. et 
al., 2008 ) . The presence of HIV decreases the sensitivity of smear 
microscopy and complicates the diagnosis of TB   ( Lawson L. et al., 
2008 ). In Abuja, Nigeria Chest X-rays (CXR) were graded by 2 readers 
(Lawson L et al., 2008 ). In USA.  Chest radiographs (CXR) help in the 
diagnosis of pulmonary TB, but may be normal and  the rate of normal 
Chest X-rays among persons with culture-confirmed pulmonary TB was 
high ( Pepper T. et al., 2008 ). 
In Vietnam, a large proportion is screened for TB annually, and one in 
five persons screened is classified as a TB suspect based on CXR. Annual 
CXR may be a high-yield, inexpensive method for TB screening but the 
follow-up of TB suspects to confirm diagnosis and initiate treatment is 
crucial (Shah N.S. et al., 2008).The presence of cavitary disease has been 
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shown to be an important risk factor for treatment failure and relapse and 
possibly for development of drug resistance during treatment ( Moises 
Palaci et al., 2007). 
 
1.7 Anti tuberculous. Drugs 
 
1.7.1 First line anti tuberculous Drugs  
Since after the first streptomycin 1944 trials, anti-tuberculous 
chemotherapy research has been focused upon establishing drug 
combination regimens capable of overcoming drug resistance . The first 
milestone being the 1959 Madras trial comparing home and sanatorium 
treatment in South India. Subsequently, the  trials led Fox and Mitchison 
to indicate rifampcin ( R ), isoniazid ( H )and pyrazinamide ( z ) as the 
first line drugs for short course, 6 month, regimens and the 1982 Hong 
Kong Chest Service trials established intermittent therapy as the 
ambulatory treatment standard for directly observed therapy (Salini C., 
2006 ) .In Spain the pharmacological therapy has shown greatest efficacy,  
it consists of two months of isoniazid, rifampcin and pyrazinamide 
followed by four additional months with the first two drugs (Boldú J. et al 
., 2007) .  
Therapy for uncomplicated drug-sensitive pulmonary tuberculosis 
consists of : isoniazid (5mg\kg up to 300 mg \ day ) , Rifampcin (10 
mg\kg \ day up to 600 mg daily and Pyrazinamide (15 to 30 mg\kg \day 
or maximum of  2 g \ day ) . If the treatment is appropriate, clinical 
improvement is readily developed in the vast majority of patients with 
pulmonary tuberculosis, efficacy usually becomes obvious in the first 2 
weeks which is evidenced by reduction of fever, cough, weight gain and 
increase in the sense of well being. Always 90% of patient who receive 
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optimal treatment will have negative cultures within 3 to 6 months 
(Alfred Goodman Gilman, 2001). 
Streptomycin (S) is an amino glycoside antibiotic derived from cultures 
of      Streptomyces  Griseus  fungus ( Gerald K. Mc Evoy et al., 1988  ) 
and it is classified as a first line antituberculous drug , bacterial resistance 
develops rapidly in many organisms , the MIC range between 1 to 8 
ug\ml. Usually given intramuscular injection in a dose  of 15 to 20 mg\kg 
daily , 50 mg\kg can be given intermittently twice or three times a week 
(james et al., 1996). 
Isoniazid ( INH) is a synthetic isonicotinic acid hydrazide with 
antituberculous activity ( Gerald K. Mc Evoy et al., 1988  ) , it is 
considered as a main stay of primary treatment of pulmonary and extra 
pulmonary tuberculosis , it acts as a rapid bactericidal against actively 
dividing Mycobacterium Tuberculosis , with less sterilizing activity than 
rifampcin and pyrazinamide .The usual dose in the daily regimen is 
5mg\kg , in UK 10 mg\kg daily has been recommended for children , a 
dose of 15mg\kg is recommended twice or three times weekly in the 
intermittent regimen (james et al., 1996).  
Concerning the pharmacokinetics of INH, it is rapidly absorbed from 
Gastrointestinal tract, highly diffused to body tissues and body fluids, 
metabolized  through acetylation, which depends on genetic variations 
either rapid acetylators or fast acetylators (Rang et al., 1995). Among 
patients who developed hepatotoxicity in Brazil , (64.3%) were slow 
acetylators and  (35.7%) were fast acetylators ( Possuelo et al ., 2008 ). 
According to (Alfred Goodman Gilman ,2001) and ( Gerald K. Mc Evoy 
et al., 1988  )   Isoniazid , rifampcin and pyrazinamide are given for 2 
months , isoniazid  and  rifampcin  are then continued for 4  additional  
months ,often after diagnosis and initial therapy , prolonged bed rest is 
not necessary or even helpful in speeding  recovery .Among 
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Rifampcin (R) is a semi synthetic derivative of  Rifamycin B ,  an 
antibiotic derived from Streptomyces  Mediterranei  fungus ( Gerald K. 
Mc Evoy et al., 1988  ) .also is a potent anti tuberculous drug with 
bactericidal as well as sterilizing properties as 10 mg/kg body weight. 
(Diacon A.H. et al., 2007). It acts as a bactericidal against wide range of 
microorganisms by inhibition of DNA-dependant RNA .the usual dose  is 
10 mg\kg\day by mouth on an empty stomach or 15 mg\kg twice or three 
times weekly in the intermittent regimen (james et al., 1996). 
Pyrazinamide (PZA) is a derivative of niacinamide act as a synthetic 
antituberculous agent ( Gerald K. Mc Evoy et al., 1988  ) .It is a first line 
agent used in the initial multi-drug phase of tuberculosis treatment for 8 
weeks . the recommended dose by mouth up to 36 mg\kg daily or 75 
mg\kg twice or three times weekly (james et al., 1996). 
Ethambutol hydrochloride  ( EMB) is a synthetic antituberculous agent 
( Gerald K. Mc Evoy et al., 1988  ) . it is classified as a bacteriostatic 
agent against Mycobacterium Tuberculosis with MIC of  0 .5  to  8 ug\ml 
, in higher concentration it acts  as a bactericidal with a sterilizing activity 
. Administered by mouth in a dose of 25 mg\kg daily for 8 weeks or  30  
to 40 mg twice weekly in the intermittent regimen (james et al., 1996). 
Rifampcin and Pyrazinamide show Bactericidal in addition to the 
sterilizing property, but Pyrazinamide shows the sterilizing property only 
during the intensive phase  ( MitchisonD.A., 2005). While isoniazid 
prevents the emergence of drug resistance (Mitchison D.A., 2004) 
Ethambutol , an effective anti- tuberculosis drug , which is generally well 
tolerated , its main adverse reaction being optic neuritis. Other 
uncommon adverse effects include arthralgia, skin rash, peripheral 
neuropathy, hepatitis, malaise, gastrointestinal upset, mental confusion, 
headache, dizziness and fever ,
 
a case of Ethambutol-induced. flu like  
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syndrome  was been reported in India  , althougth  review of literature did 
not give any report of similar cases  ( Rajinder Singh Bedi et al., 2000 ). 
 
1.7.2 Second line anti tuberculous. Drugs 
  Ethionamide is a synthetic  nicotinic acid derivative  with anti 
tuberculous activity .Cycloserine is an antibiotic derived from 
Streptomyces  Garyphalus , fungus or it is a structural analogue of  D-
alanine  amino acid also it can be produced synthetically .Capreomycin is 
a polypeptide antibiotic derived from Streptomyces  Capreolus fungus  as  
a complex of  four microbiologically  active components    (Gerald K. Mc 
Evoy et al., 1988  ) . Kanamycin is an amino glycoside antibiotic derived 
from cultures of Streptomyces  Kanamyceticus  fungus as a complex of 
three components with a various degree of microbiological activity   
(Gerald K. Mc Evoy et al., 1988  ) . 
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Table (1.1) showing the official doses of antituberculous drugs 
 
International Union Against TB 
 
American Thoracic Society 
Daily dose 
 
 
 
 
 
Drug 
<50 Kg 
 
>50 Kg 
 
Twice 
weekly 
 
Daily dose 
 
 
Twice weekly 
INH 300 mg 450 mg 600-900 mg 5-10 mg\kg 15 mg\kg 
Rifampcin 450mg 600mg 600mg 10-20mg\kg 25-30 mg\kg 
Streptomycin IM 0.75 g 
 
1 g Up to   1 g 15-20 mg\kg 25-30 mg\kg 
Ethambutol 1.2 g 
 
1.5 g 2.4 g 15-25 mg\kg 50 mg\kg 
Pyrazinamide 1.5 g 
 
2 g 3 g 15-30 mg\kg 50 mg\kg 
Ethionamide 0.5 g 
 
0.75 g 
 
300 g 
 
15-30 mg\kg 50 mg\kg 
Cycloserine 0.75 g 
 
1 g 300 g 10-20 mg\kg 50  mg\kg 
Kanamycin IM 0.75 g 
 
1 g 300 g 10-30mg\kg 50 mg\kg 
capreomycin IM   300 g 50 mg\kg 50 mg\kg 
Viomycin    IM   300 g 50 mg\kg 50 mg\kg 
 
(Toman K., 1989). 
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1.7.3 Adverse drug reactions 
 
In general the adverse effect of aminglycosides are nephrotoxicity , 
neurotoxicity ,ototoxicity (  Laurence et al., 1997 ) .  
risk of peripheral neuritis is the main adverse effect of isoniazid specially 
in patient with poor nutrition , transient increase in liver enzymes occurs 
in 10 to 20% of the patients during the first few months of treatment and 
usually return to normal despite continued treatment, isoniazid should be 
stopped if hepatic damage is confirmed, neurological adverse effects 
including psychiatric reactions and convulsions, hematologically  various 
types of anemia, agranulocytosis ,thrombocytopenia and eosinophilia are 
developed (James et al., 1996).. Isoniazid is a structural analogue of 
pyridoxine and it accelerates its excretion leading to peripheral neuritis , 
also it can cause hepatitis within 8 weeks which is caused by its active 
metabolite acetylhydrazine    (  Laurence et al., 1997 ) .  
Pyridoxine 15 to 50 mg\day should be indicated to minimize the adverse 
effects of isoniazid (sinder D.E., 1980 ). 
The major adverse effects of rifampcin include : GIT disturbances , 
nausea , vomiting , anorexia and epigastric disorders , CNS disturbances 
including : drowsiness , ataxia dizziness , and visual disturbances were 
developed , in addition to muscular weakness, thrombocytopenia , 
transient abnormalities in the liver enzymes and pseudomembraneous 
colitis  (james et al., 1996).the main adverse effects of pyrazinamide are : 
hepatotoxicty (transient elevation of liver enzymes in less than 3%of the 
patients ), hyperuricemia , anorexia , nausea , vomiting , anemia , 
arthralgia , dysurea  and skin rash (james et al., 1996). 
The most important adverse effect of ethambutol is a dose - related visual 
disturbance associated with retro bulbar neuritis (james et al., 1996).  
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According to WHO 2006, rifampcin, isoniazid, ethambutol, and 
pyrazinamide can be used during pregnancy. Streptomycin is not given 
due to ototoxicity to the fetus 
In Spain the first line antituberculous drugs are well tolerated, but they 
can produce potentially serious secondary effects that need a proper 
knowledge and  management (Boldú J. et al ., 2007) . 
Data regarding the safety profile of anti tuberculous drugs were lacked in 
Nepal ( P .V .K.et al., 2008 ), where the most common adverse drug 
reactions  were elevated liver enzymes  (57.14%) and hepatobiliary 
system was the most common system affected  (58.5%). In (52.55%) of 
the patients, these adverse drug reactions were developed within 20 days 
of initiation of therapy. Isoniazid and pyrazinamide were the suspected 
drugs responsible for 32.32% each of the total adverse drug reactions . 
The most common laboratory abnormality observed was elevated SGOT 
level in (52.5%) of the patients ,  (17.5%) patients needed specific drug 
treatment for managing the Adverse Drug Reactions (ADRs) and  (25%) 
needed symptomatic management and (87.5%) of the patients recovered 
following the ADR. Multiple drug therapy led to the development of 
(75%) ADRs. It was found that  (72.5%) of the ADRs were probably due 
to the suspected drugs  , (47.5%) of the ADRs were mild , it was found 
that ADRs to anti tuberculous drugs are common Since TB is a common 
problem therefore , special efforts are needed to tackle the drug related 
complications associated with antituberculous  drugs ( P .V .K.et al 
2008). 
In Ethiopia anti-TB Drug Induced Hepatotoxicty  is a major problem in 
HIV-associated TB with a decline in immune status and that there is a 
need for a regular biochemical and clinical follow up for those patients 
who are at risk and  Stepwise restarting of anti TB treatment was  
successful in almost all the patients who developed clinical Drug Induced 
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Hepatotoxicty (Yimer G. et al ., 2008 ). Nephrotoxicity and ototoxicity 
are the main adverse effects of Capreomycin ( Gerald K. Mc Evoy et al., 
1988  ) .  
 
1.7.4 Multi –drug resistance (MDR) 
 
multi –drug resistance to Tuberculosis (MDR) is an important public 
health problem worldwide due to  the advent of multidrug resistant strains 
(MDR) and the lack of new drugs in the market ( de Souza M.V., 2006 ). 
Reappraisal of global multi and resistance data suggest that the problem 
is more critical in sub-Saharan African countries (Nerney R.M.C. and 
Zager E., 2007). 
One of the more important problems in the chemotherapy of T.B is the 
development of bacterial resistance due to poor patient adherence . 
Because of the increasing frequency of drug resistance , the center of 
diseases control (CDC) recommended that initial therapy should be with a 
four drugs regimen isoniazid , rifampcin , pyrazinamide and Ethambutol 
or streptomycin  (Alfred Goodman Gilman ,2001).  
 In Zimbabwe, other countries in Africa and world-wide, TB treatment 
and control face new difficulties including the impact of multi-drug 
resistance (Houston S.,et al.,1991). 
Among the estimated 9 million new cases that are annually recorded 
worldwide, antibiotic drug resistance of Mycobacterium tuberculosis has 
become an increasing problem. Cases of multidrug resistance (MDR), by 
definition are resistance against at least isoniazid and rifampcin, 
Moreover, cases of extensively drug-resistant ( XDR ) tuberculosis with 
additional resistance to fluoroquinolones and aminoglycosides are also 
emerging (Greinert U. et al ., 2007). 
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In Karachi , Primary resistance to at least one drug was 7.0% and no 
MDR. Among individual drugs, resistance to Isoniazid was highest (14%) 
and lowest for Pyrazinamide (1.4%)  ( Akhtar S. et al., 2007 ). 
The emergence of multidrug-resistant (MDR)-TB and, more recently, of 
extensively drug-resistant (MDR)-TB is a real threat to achieve TB 
control and elimination. The prevalence of MDR-TB and XDR-TB are 
inversely correlated with the quality of TB control and the proper use of 
second-line anti-TB drugs. Adherence to proper standards of care and 
control is a top priority of all TB control efforts. However, the risk of an 
uncontrollable epidemic of MDR- and XDR -TB is a real considering 
current issues that need  financing and commitment to care (Matteeli A. et 
al., 2007) . 
In Kinshasa , the primary resistance rate reached 43.5%; it reached 31.6% 
in 1990. The multi-drug-resistance rate (MDR-TB) notified as resistant to 
both rifampcin and isoniazid rose to 5.3%. This rate of primary resistance 
is among the highest in Africa (Kabedi M.J. et al., 2007). 
The emergence of extensively drug-resistant tuberculosis confirms that 
problems in tuberculosis management are still present in Europe. While 
waiting for new tools which will facilitate management of extensively 
drug-resistant tuberculosis, accessibility to quality diagnostic and 
treatment services should be urgently ensured and adequate public health 
policies should be rapidly implemented to prevent further development of 
drug resistance  (Migliori G.B. et al ., 2007). 
Factors associated with MDR-TB included age under 45 yr, previous TB 
treatment, and the presence of cavitations on chest radiography. Rates of 
first-line drug resistance are high, particularly in previously treated 
patients, in the private sector in Korea. This underscores the need for an 
improved control program, coupled with early diagnosis of MDR-TB, to 
reduce the spread and development of resistance (Choi J.C. et al .,2007 ). 
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The findings of  ( Kehinde A.O. et al ., 2007 ) shows that MDR-TB is 
emerging in Nigeria . Therefore , Further studies on MDR-TB are 
urgently needed in the country to ascertain the magnitude of the problem 
to propose  proper solutions . 
According to Morbidity and Mortality Weekly Report of New York City, 
hospital 1993, From January 1991 through July 1992, multidrug- resistant 
(i.e., resistance to at least isoniazid  and rifampcin  Mycobacterium 
tuberculosis was isolated from  (22%) of patients with newly diagnosed 
TB at  New York City hospital.  
Recently, serious concerns about extensively drug-resistant tuberculosis , 
which shows resistance to second-line anti-TB drugs in addition to 
isoniazid and rifampcin, have been raised ( Kim H.R. et  al ., 2007). 
In Australia , (90.5%)  of  in vitro tuberculosis isolates were  from new 
cases , (9.1%) of them were resistant to at least one of  anti-tuberculosis 
agents , resistance to at least Isoniazid  and Rifampcin  was found in 
(1.5%)  which was considered as a multi-drug resistance  ( Lumb R. et al 
., 2007) 
tuberculosis isolates resistant to at least one of the standard drugs, 67 
(90.5%) were from new cases, 
To enhance the efficacy of anti-TB therapy in drug-resistant patients is 
the key of improving the outcome (Wang X. et al., 2001). 
 
1.8 Patient adherence 
 
Patient adherence is a crucial to the success of antituberculous therapy , 
patients should be taught the necessity of adhering to the drug regimen 
for the full duration of treatment ( Gerald K. Mc Evoy et al., 1988  ) 
The WHO estimates that only 48% of TB cases are detected in Malawi. 
The complexity of TB diagnosis requires repeated visits, long queues, and 
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delays in sending results. This reduces patient ability to access and adhere 
to services ( Simwaka B.N. et al ., 2007).  
By improving compliance, can improve results and the cost-effectiveness 
of therapy. Intermittent therapy reduces drug costs and allows for the 
possibility of complete supervision many TB treatments fail due to poor 
patient compliance. For therapy to be successful, compliance is a must ( 
Braush L.M. ans Bass J .B. 1993 )  
Despite having  drug logistics, the main challenge was to maintain 
patients on such prolonged treatment by identifying a provider closer to 
the patient who can also give injection, have social skills and manage of 
minor adverse reactions (Thomas A. et al ., 2007 ). 
Treatment adherence identified as an impediment to the successful 
control of T.B. in Timor leste (Martins N. et al., 2007). 
Treatment failure may be due to irregular or in adequate therapy caused 
by poor patient adherence, the use of single drug with interrupting 
treatment due to toxicity or hypersensitivity, an in adequate initial 
regimen and primary resistance of microorganism (Alfred Goodman 
Gilman, 2001). 
Directly observed therapy for TB is associated with better adherence to 
therapy and survival (Alwood K., et al 1994). In Spain difficulties of the 
treatment of tuberculosis were due to complying with the treatment, as 
well in follow-up and control (Boldú J. et al., 2007). For improving 
compliance , in Romania , the individual health education, cooperation 
with psychologist or psychiatrist, the final compulsory isolation of the 
nonsocial patients are recommended (Bicică V et al 1991). 
In Timor leste preference of traditional Medicines, economic difficulties 
and Geographical remoteness are the main obstacles of T.B. treatment 
and Provision of food with high level of knowledge including correct 
under standing how it is cured assist patients to complete the treatment 
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(Martins N. et al., 2007). And in Zimbabwe, many TB treatments fail due 
to poor patient compliance (Houston S.,et al.,1991). 
 
1.10 The situation of Tuberculosis in Sudan 
 
Till 1998 Sudan was classified as one of the slowly moving countries in 
implementation of  the DOTS strategy and  making no progress against 
TB (Wise J., 1998 ). 
Tuberculosis, whose indications are heavy coughing and expectoration, 
was also rampant in southern Sudan (Veeken H., 1998). 
In 2002 according to Sudan National Tuberculosis Programme progress 
report 2005, DOTS was  declared all over, the activities in 2003 were 
focused on furthur strengthen of DOTS and by 2004 -2005 it was planed 
to fulfill the WHO targets (70% case detection and 85% cure rate) Sudan 
National Programme .  
According to Sharaf- Eldin G.S., 2002, In Khartoum state drug resistance 
was a serious problem   and it might complement the efforts of the 
National Tuberculosis Programme to improve strategies to control this 
disease. 
In Khartoum , Red Sea and Gadaref States , facilities provide care for a 
higher proportion of women and older age groups of tuberculosis 
patients, suggesting  higher level of accessibility for these groups. A 
higher cure rate and a lower default rate were noted in  referral hospitals 
and primary health care ( PHC ) facilities, possibly reflecting better 
conditions for directly observed treatment and follow-up ( El-Sony A.I. et 
al., 2003 ). 
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1.12 Study objectives 
 
  - To evaluate the efficacy of intermittent TB chemotherapy compared to 
the daily short course regimen in regards to: 
• Clinical success rate. 
• Default  rate. 
• Adherence to treatment. 
• Relapse rate. 
• Acceptability . 
• Adverse drug reactions including hepatotoxicty . 
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2. Material and Methods 
2.1  Material 
Item Quantity Company 
Chest x ray 1000 films Agfa film Belgium  
Carbol fuchsin 4 bottles Merck Ltd India 
Methylene blue 4 bottles Sientific Ltd UK 
Liquid phenol 2 bottles  
Sulphuric acid 3 bottles  GPR 
Rifampcin + INH tablets 30.000 tablets Svesra India 
Pyrazinamide tablets 30.000 tablets Svesra India 
Ethambutol tablets 30.000 tablets Svesra India 
Streptomycin injection 6000 vials Svesra India 
Pyridoxine tablets 30.000 tablets Citypharm Sudan 
Disposable syringes  2000 syringes  
Alanineamino transferase (ALT) kids 400 kid Biosystems Spain 
Aspartate aminotransferase (AST) kids  400 kid Biosystems Spain 
Distilled water 5 liters  
Ethyl alcohol 5 liters  
Slides  400 slides Marienfeld 
Spectrophotometer Biosystems BTS-310 1 Biosystems Spain 
 ESR pipette 1 Westergreen 
 ESR stand 1 Westergreen 
Automatic pipettes (50 and 100 UL)  2 Brand GMBH 
Germany 
Centrifuge 1 Nickle Electro Ltd 
Microscope GMBH 20-518-500 1 Leika  
Developer (compound of metol hydroquinone )  Kodak France  
Fixer(sodium thiosulphate )  Kodak France 
X ray machine  1 Shimadzu Japan  
Immersion oil  1 liter Scientific Ltd UK 
Blood containers 800 HNTE Ltd UAE  
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2.1 Study design 
A prospective comparative, randomized clinical trial, hospital based 
study.   
                                                                                                            
2.3 Study area 
As it is known that the White Nile State is one of central Sudan states, 
extended to about 400 Kilometers at the southern part of Khartoum and it 
is neighbored by six Sudanese States. The predominant climate is poor 
Savannah. Agriculture and animal breeding are the most common 
economic activities. the study area includes many development projects 
e.g. Kenana and Assalaya Sugar factories , Rabak Portland Cement 
factory.  
Kosti province is inhabited by different ethnic groups also it constitutes 
more than 40% of the population of the state (702000 out of 2000000). 
This study was conducted in Kosti teaching hospital at a distance of 312 
Kilometers south of Khartoum which the major referral hospital of the 
White Nile State. Other 15 T.B centers were initiated in the state by the 
Local T.B. control programme.  
  
2.4 Study population  
New smear positive pulmonary Tuberculosis patients who attended to 
department of chest at Kosti Teaching hospital during March 2006 to 
March 2008 were enrolled in this study. 
The inclusion criterias for the sampled patients were as follows: 
o Adult > 15 years old 
o Three sample sputum smear positive pulmonary case. 
o No associated debilitating diseases or advanced disseminated 
cases.   
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2.5 Sample Size and sampling procedure  
It is that no reliable results addressing the incidence or prevalence of 
tuberculosis in the study area, depending on the proper records available 
in TB programme in the White Nile State, sample size was calculated as 
follows: 
- The average of smear positive tuberculous patient attending chest 
department at Kosti teaching hospital for the last 5 years ( 2001—
2005) was calculated ( 550 patient ) . 
-  According to Eldahian 2002 and Bayioumi 2006 , when the P 
value is <0.05,  the   minimum sample size for each  community of 
a study is summarized  in annex (1)           
- Utilizing the abovementioned avarage , according to Eldahian 
2002 and Bayioumi 2006 the minimum sample size to be admitted 
for this study was 226 patient , but 275 patients were introduced to 
the study . 
 
2.6 Data collection  
2.6.1Preparation of the field of the study 
The field of the study was prepared by frequent visits, to initiate 
good relations with the working staff, which allowed and ensured a 
maximum fruitful co-operation. 
 Chest specialist, physicians and other doctors at the private sector 
were informed that such a study will be conducted at Kosti Teaching 
Hospital and they were requested to send the targeted tuberculous patients 
to the investigator immediately after diagnosis.  
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2.6.2 Drawing a sample for therapeutic intervention   
The patients were randomized using lottery into two groups : 
Group (A) the intermittent regimen group  these patients were treated 
using ethambutol( 20mg/kg ) , rifampcin( 10mg\kg)\ isoniazid( 6mg/kg ) 
and pyrazinamide ( 25mg/kg ) for two months as an initial phase then 
were given the minimum intermittent dosage of rifampcin 900mg( 
30mg/kg)\ isoniazid 450mg( 15mg/kg ) twice weekly ( about 12 tablets\ 
week )for four additional months . 128 patients were enrolled.               
Group (B) the short course daily regimen group  these patients were 
treated using streptomycin (15mg ) , rifampcin ( 10mg/kg )\ isoniazid 
(6mg/kg) and pyrazinamide( 25mg/kg ) for two months as an initial phase 
then rifampcin ( 10mg/kg )\ isoniazid (6mg/kg )  once daily (about 21 
tablets\ week) for four additional months , 147 patients were enrolled.  
One of the objectives of the study, was to assess the acceptability of the 
patients to two different regimens, which was done by testing tow 
different dosage forms tablets (Ethambutol) against injections 
(Streptomycin), also the study aimed to compare the adopted rifampcin 
dependant daily regimen including Streptomycin against the modified 
intermittent regimen including Ethambutol i.e the comparison was done 
against the adopted regimen without modification.   
                         
2.6.3 Data collection tools 
- Closed questionnaire was designed to obtain Personal data and other 
data concerning history, symptoms of the disease (annex 3 and 4), 
clinical success rate (annex5 and 6), improvement of symptoms was 
assessed clinically according to the answers of patients, adverse 
reactions of antituberculous drugs (annex 7and 8), the prevalence of 
Tuberculosis among age, sex groups and the prevalence of smoking 
among tuberculous patients. 
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- According to the answers of patients, the progress of TB symptoms was 
assessed as complete improvement (when the symptom was completely 
disappeared and it was scored as100%), partial improvement (when the 
symptom was on and off and it was scored as 50%) and not improved 
(when the symptom was not disappeared and it was scored as others) 
- Sputum smear to evaluate the efficacy and relapse rate of chemotherapy   
in regards to microbiological success rate. 
- Chest X-ray success to evaluate the efficacy of chemotherapy in regards 
to radiological success rate. 
- Blood sample to determine liver enzymes and erythrocyte sedimentation 
rate (ESR).  
 
2.6.4 Follow up of patient and method of supervision during the 
study 
Directly Observed Therapy (DOT) and closed supervision was applied, 
Patients were given instructions to come to Kosti teaching hospital 
regularly in two weeks interval; patients who did not completely adhering 
to the regimen were considered as defaults and excluded, patient was 
considered cured after completing the treatment wiyh negative sputum. 
The patients were visited frequently in the villages and community 
leaders were involved to help in encouraging patients to adhere to 
treatment and follow up of relapse.  
The patients were supplied with food supplied for the patient and his \ her 
family  during the course of treatment  , which was provided by the 
United Nation World Food programme  in co-operation with the 
Sudanese Environmental Conservation  Society  \The White Nile Branch 
, this was an encouraging factor  to adhere to treatment and follow up see 
annexes ( photos). A total of 71 patients (55.5%) were cured in group A 
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(intermittent regimen group) and 67 patients (45.6%) in group B (daily 
regimen group). 
 
2.6.5 Sputum investigation  
-Sputum smear was prepared, left to dry at room temperature and heated, 
to fix the dry smear. 
- The smear was covered with carbol fuchsin then the stain was heated 
until vapor just begins to rise without overheating (about 60 c) then left 
for 5-10 minutes. 
-The stain was washed with clean water, covered with sulfuric acid, 
washed again with clean water, covered with methylene blue for 30-60 
seconds and washed with clean water. 
- The back of the slide was cleaned and placed on the drying rack. 
-The smear was examined microscopically using 100x power and 
immersion oil. 
- Mycobacterium Tuberculosis as an acid fast bacilli appear as a red, 
straight or slightly curved rods, singly or in a small groups.  
 
  2.6.6 Radiological examination  
Chest X-ray was done in a posterioanterior position for each patient 
initially before starting the treatment and another one by the end of the 
treatment (after six months). 
X-Ray films were processed as follows: 
-The films were immersed in to the developer tank to convert the latent 
image to a visible one, rinsed in normal water, immersed in to a fixer 
tank to fix the image then washed with water to remove the fixer. 
-The films were dried on air and labeled. 
- X-ray films were read and investigated by an expert Radiologist then the 
initial and the final X-ray films were compared for the patients who 
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completed the course of therapy using the  scores of the National TB 
association of the USA 1961: 
 : 
- Minimal Lesion: For single lesion left, right, upper or lower.  
- moderate lesion: for two lesions in two lungs.  
- Moderately advanced lesions: for more than two lesions in different 
zones (bilateral lesions). 
- Far advanced lesion: involve two lungs in two different zones. 
 
2.6.7   Erythrocytes Sedimentation Rate (ESR) determination  
2.6.7.1  Preparation of tri sodium citrate solution 
-32 g of tri sodium citrate powder were carefully weighed, transferred to 
a volumetric conical flask pre-marked to 1 Liter and the volume was 
gradually completed to I Liter with distilled water and well mixed. 
     
2.6.7.2 Determination of ESR 
-0.4 ml of sodium tricitrate in a small blood container then added to1.6 ml 
of venous blood in. 
- The citrated blood was drawn to the 0 mark of Westergreen pipette 
using safe suction method avoiding air bubble and read after one hour 
using a timer. 
 
2.6.7.3Closed questionnaire filling  
Closed questionnaire was designed, tested and carefully filled. 
 
2.6.8 Follow up of patients weights  
Regular weighting the patients initially and at the end of the course of 
treatment, registered and the means were analyzed.  
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2.6.9 Follow up of relapse rate and patient satisfaction  
Patients who completed the course of treatment 71 in group A and 67 in 
group B were requested to come regularly at the end of the third, sixth, 
12th and 18th month providing two samples of sputum that were 
investigated and the patients were asked about the symptoms of TB they 
were complaining of and they were clinically assessed by chest physician  
Also patient satisfaction form was filled for each patient (annex 9 and 
10). 
 
2.6.10 Liver enzymes assay 
Liver functions was assessed by spectrophotometrical assay of Alanine 
Amino transferase (ALT) and Aspartate Aminotransferase (AST)enzymes 
using Biosystems BTS-310 Spectrophotometer (full automatic) 
-Reagent A  (Tris 150 mmol \ L,L-Alanine 750 mmol\L, Lactate 
dehydrogenase 1350U\L,PH 7.3). 
- Reagent B ( NADH 1.3 mmol\L, 2 Oxoglutarate  75 mmol\L, sodium 
hydroxide 148 mmol\L, sodium azide 9.5 g\L )   
- working reagent was prepared by addition of 4 parts of reagent A with 1 
part of reagent B and gently mixed.  
-A sample of 100UL serum was added to the already automatically 
sucked 50 UL of the working reagent, well mixed then read after 1 
minute. 
- 5 ml of Blood sample was taken initially from each enrolled patient of 
the two groups to assess ALT and AST enzymes; this was repeated by 
the end of the second and the fourth month for those who were not 
interrupt the treatment, 
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- The initial results of the sample of ALT and AST enzymes were 
compared to the results of the second and the third samples.    
 
 
2.7 Ethical consideration 
A written consent from the local health authority was already taken 
(annex 2) and each patient was informed and consented individually , the 
first question in the questionnaire was: do you agree to be enrolled in the 
sample of this study . Each patient gain benefits of free X-ray, sputum, 
ALT,  AST, ESR investigations and antitubercular  drugs, in addition to 
assurance of free chest physician consultancy and food supplies , patients  
who do not agreed were excluded keeping their right of receiving free 
drugs, sputum investigation ,chest physician consultancy and food 
supplies was assured . 
 
2.8 Data analysis 
The raw data were introduced into SPSS program for the performance the 
descriptive and comparative analysis. The data comparison was carried 
out by Pearson Chi square and pair independent sample student T-test. 
The level of significant (P<0.05).   
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3. The results 
 
The results of a descriptive study analyzing the distribution of TB by 
age, sex, education and smoking are presented in the charts (3.1 to 3.4). 
The progress of sputum microscopy is presented in table (3.1). 
The radiological findings and progress are presented in table (3.2 to 
3.4) and figures (3.5 to 3.10). 
Occurrence of TB symptoms and the progress of these symptoms are 
presented in figure(3.11) and tables (3.6 to 3.16). 
The progress of weights of tuberculous patients is presented in figure 
(3.13).  
Table (3.17): percentage of patients cured. 
Figure (3.14) presents the adherence to treatment in relation to time. 
Table (3.18) presents results of relapse rate. 
Figure (3.15) presents patient Satisfaction. 
Concerning the adverse drug reactions, tables (3.19 to 3.26) present 
the means of Alanine Aminotransferase (ALT) and Aspartate 
Aminotransferase (AST)enzymes among the two groups,within the group 
and the number of patients with an elevated liver enzymes.  
Peripheral neuropathy, gastrointestinal disturbances, abdominal pain, 
Itching, and arthritis are presented in the tables (3.26 to 3.30).    
Treatment outcome in group A and B is summarized in Figure (3.16) 
 
 
 
 
 37
 
Figure (3.1):    Age and sex distribution of the study population 
(group A and B) 
 
N = 275 patients 
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P-value = 0.723 
 
Group ( A ) the intermittent regimen group EMP\R\INH\PZA  for 2 
months then R\ INH twice weekly for 4  months .       
Group ( B )  the short course daily regimen group S\R\INH\PZA for2 
months then R\ INH once daily for 4 months .     
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Figure (3.2):          Education among the study group 
                               N = 275 patients 
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P – Value = 0.053 
 
Group ( A ) the intermittent regimen group EMP\R\INH\PZA  for 2 
months then R\ INH twice weekly for 4  months .       
Group ( B )  the short course daily regimen group S\R\INH\PZA for2 
months then R\ INH once daily for 4 months .                          
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Figure: (3.3)      :       Percentage of cigarette smoking among the 
study population (group A and B) 
N = 151 
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Figure: (3.4):                Percentage of Shisha smoking among the 
study population (group A and B) 
N = 151 
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Table (3.1):   Sputum microscopy during the course of treatment 
N = 138 patients 
 
GROUP Pearson Chi-Square 
Group A Group B 
Total 
 
No % No % No % 
Value P-Value 
+ ve 2 2.8% 0 0 2 1.4% At the end of 
the First 
month - ve 69 97.2% 67 100.0% 136 98.6% 
1.915 0.166 
+ ve  0     0% 0 0% 0 0% At the end of 
the Second 
month - ve 71 100.0% 67 100% 138 100% 
0.00 0.00 
+ ve 0    0% 1 1.5% 1 .7% 1.067 .302  At the end of 
the Third 
month - ve 71 100.0% 66 98.5% 137 99.3%   
+ ve 0 0 0 0 0 0 0.00 0.00 At the end of 
the Fourth 
month - ve 71 100.0% 67 100.0% 138 100.0%   
+ ve 0 0 0 0 0 0 0.00 0.00 At the end of 
the Fifth 
month - ve 71 100.0% 67 100.0% 138 100.0%   
At the end of 
the Sixth 
month 
+ ve 0 0 0 0 0 0 0.00 0.00 
 - ve 71 100.0% 67 100.0% 138 100.0%   
 
 
 
Group ( A ) the intermittent regimen group EMP\R\INH\PZA  for 2 
months then R\ INH twice weekly for 4  months .       
Group ( B )  the short course daily regimen group S\R\INH\PZA for2 
months then R\ INH once daily for 4 months . 
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Table (3.2)    Initial radiological findings among the study group of 
tuberculous patients 
 
N = 275 patients 
 
 
Percentage Frequency Lesion 
55 152 Consolidation  
31 85 Normal chest X-ray  
4 11 Cavity  
3.6 10 Pleural effusion  
4.4 12 Nodular  
0.8 2 Linear fibrosis  
0.4 1 Adenopathy  
0.8 2 Calcification 
0 0 Bronchiectasis  
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Figure (3.5)  Severity of TB lesions in the initial X-Ray film among 
cured patients (group A and B) 
 
N – 138 patients 
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Figure (3.6)  Distribution of TB lesions in the two lungs (left and 
right) 
N = 275 patients 
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Table (3.3) Distribution of TB lesions at different lungs zones among 
the study population (group A, B) 
N=98 films 
 
Right lung Left lung  
Number % Number % 
Upper zone 10 5.9% 8 20.5% 
Middle zone 6 3.54% 5 12.82% 
Lower zone 17 10.03% 12 30.76% 
Upper and middle zone 9 5.31% 6 15.38% 
Upper and lower zone 0 0 0 0 
Middle and lower zone 7 4.13% 4 10.25% 
Upper middle and lower 10 5.9% 3 7.69% 
Total  59 100% 39 100% 
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Table (3.4)  Bilateral distribution of TB lesions at different lung 
zones among the study population (group A,B) 
N = 95 
 
 
Zones No of 
(films) 
percentage
Upper \ upper zones 1 1% 
Lower\lower zones 21 22.1% 
Upper \upper and middle\middle zones 6 6.3% 
Middle\middle and lower\lower zones 14 14.7% 
Middle\middle zones 14 14.7% 
Upper \upper , middle\middle and lower\lower 
zones 
5 5.3% 
Other s 27 28.4% 
Total 95 100 % 
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Figure (3.7) Radiological progress of minimal TB lesion in the initial 
and final X-Ray films 
N = 27 films 
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P – Value = 00.00 
 
Group ( A ) the intermittent regimen group EMP\R\INH\PZA  for 2 
months then R\ INH twice weekly for 4  months .       
Group ( B )  the short course daily regimen group S\R\INH\PZA for2 
months then R\ INH once daily for 4 months .                 
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Figure (3.8)  Radiological progress of moderate TB lesion in the 
initial and final X-Ray films 
N = 25 films 
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Group ( A ) the intermittent regimen group EMP\R\INH\PZA  for 2 
months then R\ INH twice weekly for 4  months .       
Group ( B )  the short course daily regimen group S\R\INH\PZA for2 
months then R\ INH once daily for 4 months .                                                  
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Figure (3.9)  Radiological  progress of  moderately advanced TB 
lesion in the  initial and  final X-Ray films 
 
N = 24 films 
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Group ( A ) the intermittent regimen group EMP\R\INH\PZA  for 2 
months then R\ INH twice weekly for 4  months .       
Group ( B )  the short course daily regimen group S\R\INH\PZA for2 
months then R\ INH once daily for 4 months .                      
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Figure (3.10)  Radiological progress of far advanced TB lesion in the 
initial and final X-Ray films 
 
N = 31 films 
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P – Value = 00.00 
 
 
Group ( A ) the intermittent regimen group EMP\R\INH\PZA  for 2 
months then R\ INH twice weekly for 4  months .       
Group ( B )  the short course daily regimen group S\R\INH\PZA for2 
months then R\ INH once daily for 4 months .                                        
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Figure (3.11):    Type of cough among the study population (group A, 
B)   
N = 275 patients 
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P - Value=0.40 
 
Group ( A ) the intermittent regimen group EMP\R\INH\PZA  for 2 
months then R\ INH twice weekly for 4  months .       
Group ( B )  the short course daily regimen group S\R\INH\PZA for2 
months then R\ INH once daily for 4 months .                          
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Table (3.5)  Progress of cough symptom in the two groups 
 
N = 136 patients 
 
GROUP Pearson Chi-Square 
Group A Group B 
Total 
 
No % No % No % 
Value P-Value 
Resolved 34 48.6% 20 30.3% 54 39.7% 
Partial 
improvement  34 48.6% 44 66.7% 78 57.4% 
After 2 
wks 
Not 
improved 2 2.9% 2 3.0% 4 2.9% 
4.798 0.091 
 Resolved 51 72.9% 28 42.4% 79 58.1% 
Partial 
improvement 18 25.7% 38 57.6% 56 41.2% 
After 2 
months 
Not 
improved 1 1.4% 0 0 1 .7% 
14.734 0.001 
Resolved 63 90.0% 46 69.7% 109 80.1% 
Partial 
improvement 7 10.0% 18 27.3% 25 18.4% 
After 6 
months 
Not 
improved 0 0 2 3.0% 2 1.5% 
9.382 0.009 
 
 
 
 
Group ( A ) the intermittent regimen group EMP\R\INH\PZA  for 2 
months then R\ INH twice weekly for 4  months .       
Group ( B )  the short course daily regimen group S\R\INH\PZA for2 
months then R\ INH once daily for 4 months .                                          
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Table (3.6)           Time of fever among the two groups of Tuberculous 
Patients 
 
 
N = 127 
 
 
 
GROUP 
Group A Group B 
Total  
 
No % No % No % 
All the day 15 22% 5 8.3% 20 15.7% 
Afternoon fever 5 7.8% 4 6.7% 9 7.1% 
Time of 
fever 
Night fever 48 75.0% 50 83.3% 98 77.2% 
Total 68 100.0% 59 100.0% 127 100.0%
 
 Value P-Value
Pearson Chi-Square 1.495 0.474 
 
 
                     
   
 
Group ( A ) the intermittent regimen group EMP\R\INH\PZA  for 2 
months then R\ INH twice weekly for 4  months .       
Group ( B )  the short course daily regimen group S\R\INH\PZA for2 
months then R\ INH once daily for 4 months .                          
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Table (3.7)         progress of fever as a symptom among Tuberculous 
patients in group (A, B) 
 
N = 127 
 
GROUP Pearson Chi-Square 
Group A Group B 
Total 
 
No % No % No % 
Value P-Value 
Resolved 47 69.1% 41 69.5% 88 69.3% 
Partial 
improvement 21 30.9% 17 28.8% 38 29.9% 
After 2 
wks 
Not 
improved 0 0 1 1.7% 1 .8% 
1.198 0.549 
Resolved 61 89.7% 45 76.3% 106 83.5% 
Partial 
improvement 7 10.3% 14 23.7% 21 16.5% 
After 2 
months 
Not 
improved 0 0 0 0 0 0 
4.131 .042 
Resolved 66 97.1% 55 93.2% 121 95.3% 
Partial 
improvement 2 2.9% 3 5.1% 5 3.9% 
After 6 
months 
Not 
improved 0 0 1 1.7% 1 .8% 
1.570 0.456 
 
 
 
Group ( A ) the intermittent regimen group EMP\R\INH\PZA  for 2 
months then R\ INH twice weekly for 4  months .       
Group ( B )  the short course daily regimen group S\R\INH\PZA for2 
months then R\ INH once daily for 4 months .s                         
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Table (3.8):    incidence of sweating  as a symptom of Tuberculosis 
among the study population ( group A, B) 
 
N = 93 patients 
 
 
 
GROUP 
Group A Group B 
Total  
 
Number % No % No % 
Yes 56 78.9% 37 55.2% 93 67.4% 
Sweating 
No 15 21.1% 30 44.8% 45 32.6% 
Total 71 100.0% 67 100.0% 138 100.0% 
 
 Value P-Value
Pearson Chi-Square 8.773 0.003 
 
 
 
 
 
 
Group ( A ) the intermittent regimen group EMP\R\INH\PZA  for 2 
months then R\ INH twice weekly for 4  months .       
Group ( B )  the short course daily regimen group S\R\INH\PZA for2 
months then R\ INH once daily for 4 months .                          
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Table (3.9) : Progress of sweating among the study population  
(group A , B) 
N = 93 patients 
 
 
GROUP Pearson Chi-Square 
Group A Group B 
Total 
 
 
No % No % No % 
Value P-Value 
Resolved 31 55.4% 18 48.6% 49 52.7% 
Partial 
improvement 24 42.9% 17 45.9% 41 44.1% 
After 2 
wks 
Not improved 1 1.8% 2 5.4% 3 3.2% 
1.143 .565 
Resolved 45 80.4% 28 75.7% 73 78.5% 
Partial 
improvement 10 17.9% 9 24.3% 19 20.4% 
After 2 
months 
Not improved 1 1.8% 0 0 1 1.1% 
1.179 .555 
Resolved 52 92.9% 31 83.8% 83 89.2% 
Partial 
improvement 3 5.4% 6 16.2% 9 9.7% 
After 6 
months 
Not improved 1 1.8% 0 0 1 1.1% 
3.581 .167 
 
 
 
Group ( A ) the intermittent regimen group EMP\R\INH\PZA  for 2 
months then R\ INH twice weekly for 4  months .       
Group ( B )  the short course daily regimen group S\R\INH\PZA for2 
months then R\ INH once daily for 4 months .                           
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Table (3.10): Incidence of Loss of appetite as a symptom of 
Tuberculosis 
N = 107 patients 
 
 
GROUP 
Group A Group B 
Total  
 
No % No % No % 
Yes 61 85.9% 46 68.7% 107 77.5% 
Lost of appetite 
No 10 14.1% 21 31.3% 31 22.5% 
Total 71 100.0% 67 100.0% 138 100.0% 
 
 Value P-Value
Pearson Chi-Square 5.895 0.015 
 
 
 
 
Group ( A ) the intermittent regimen group EMP\R\INH\PZA  for 2 
months then R\ INH twice weekly for 4  months .       
Group ( B )  the short course daily regimen group S\R\INH\PZA for2 
months then R\ INH once daily for 4 months .                          
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Table (3.11):     Progress of Loss of appetite among the two groups of 
Tubercular patients 
N = 107 patients 
                        
 
GROUP Pearson Chi-Square 
Group A Group B 
Total 
 
No % No % No % 
Value P-Value 
Resolved 34 55.7% 24 52.2% 58 54.2% 
Partial 
improvement 25 41.0% 21 45.7% 46 43.0% 
After 2 
wks 
Not improved 2 3.3% 1 2.2% 3 2.8% 
.309 .857 
Resolved 49 80.3% 31 67.4% 80 74.8% 
 Partial 
improvement 12 19.7% 14 30.4% 26 24.3% 
After 2 
months 
Not improved 0 0 1 2.2% 1 .9% 
3.163 .206 
 Resolved 53 86.9% 39 84.8% 92 86.0% 
Partial 
improvement 8 13.1% 7 15.2% 15 14.0% 
After 6 
months 
Not improved 0 0 0 0 0 0 
.096 .756 
 
 
 
Group ( A ) the intermittent regimen group EMP\R\INH\PZA  for 2 
months then R\ INH twice weekly for 4  months .       
Group ( B )  the short course daily regimen group S\R\INH\PZA for2 
months then R\ INH once daily for 4 months .    
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Table (3.12): Occurrence of chest pain as a symptom of Tuberculosis 
N = 106 patients 
 
 
 
GROUP 
Group A Group B 
Total  
 
No % No % No % 
Yes 59 83.1% 47 70.1% 106 76.8% Chest 
pain No 12 16.9% 20 29.9% 32 23.2% 
Total 71 100.0% 67 100.0% 138 100.0% 
 
 Value P-Value
Pearson Chi-Square 3.245 .072 
 
 
 
Group ( A ) the intermittent regimen group EMP\R\INH\PZA  for 2 
months then R\ INH twice weekly for 4  months .       
Group ( B )  the short course daily regimen group S\R\INH\PZA for2 
months then R\ INH once daily for 4 months . 
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Table (3.13)  Progress of chest pain among the two groups of 
Tuberculous patients 
N = 106 patients 
 
 
GROUP Pearson  Chi-Square 
Group A Group B 
Total 
 
No % No % No % 
Value P-Value 
Resolved 27 45.8% 18 38.3% 45 42.5% 
Partial 
improvement 31 52.5% 27 57.4% 58 54.7% 
After 2 
wks 
Not 
improved 1 1.7% 2 4.3% 3 2.8% 
1.064 .587 
Resolved 41 69.5% 30 63.8% 71 67.0% 
Partial 
improvement 18 30.5% 14 0 32 30.2% 
After 2 
months 
Not 
improved 0 0 3 6.4% 3 2.8% 
3.896 .143 
 Resolved 54 91.5% 30 6 3.8% 84 79.2% 
Partial 
improvement 5 8.5% 15 31.9% 20 18.9% 
After 6 
months 
Not 
improved 0 0 2 4.3% 2 1.9% 
12.661 .002 
 
 
Group ( A ) the intermittent regimen group EMP\R\INH\PZA  for 2 
months then R\ INH twice weekly for 4  months .       
Group ( B )  the short course daily regimen group S\R\INH\PZA for2 
months then R\ INH once daily for 4 months .                          
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Table (3.14) : Occurrence of haemoptysis as a symptom of 
Tuberculosis 
N = 41 patients 
 
 
GROUP 
Group A Group B 
Total  
 
No % No % No % 
Yes 14 19.7% 27 40.3% 41 29.7% 
Haemoptysis 
No 57 80.3% 40 59.7% 97 70.3% 
Total 71 100.0% 67 100.0% 138 100.0% 
 
 Value P-Value
Pearson Chi-Square 6.991 .008 
 
 
Group ( A ) the intermittent regimen group EMP\R\INH\PZA  for 2 
months then R\ INH twice weekly for 4  months .       
Group ( B )  the short course daily regimen group S\R\INH\PZA for2 
months then R\ INH once daily for 4 months .                         
 
Table (3.15):  Progress of haemoptysis among the two groups of 
Tubercular  Patients 
N = 41 patients 
 
 
GROUP Pearson Chi-Square 
 
Group A Group B 
Total 
Value P-
 62
No % No % No % Value 
Resolved 14 100.0% 24 88.9% 38 92.7% 
Partial 
improvement 0 0 2 7.4% 2 4.9% 
After 2 
wks 
Not 
improved 0 0 1 3.7% 1 2.4% 
1.678 .432 
 Resolved 14 100.0% 27 100.0% 41 100.0% 
 Partial 
improvement 0 0 0 0 0 0 
After 2 
months 
Not 
improved 0 0 0 0 0 0 
  
Resolved 14 100.0% 27 100.0% 41 100.0% 
 Partial 
improvement 0 0 0 0 0 0 
After 6 
months 
Not 
improved 0 0 0 0  0 0 
  
 
 
 
Group ( A ) the intermittent regimen group EMP\R\INH\PZA  for 2 
months then R\ INH twice weekly for 4  months .       
Group ( B )  the short course daily regimen group S\R\INH\PZA for2 
months then R\ INH once daily for 4 months . 
 
 
 
 
Figure: (3.12)    Comparison between the means of initial ESR with 
the results of ESR at the end of the treatment 
N = 41 patients 
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p-value = 0 
 
Group ( A ) the intermittent regimen group EMP\R\INH\PZA  for 2 
months then R\ INH twice weekly for 4  months .       
Group ( B )  the short course daily regimen group S\R\INH\PZA for2 
months then R\ INH once daily for 4 months . 
 
 
 
  
 
 
 
 
 
 
 
Figure: (3.13) Comparison between the means of initial weight with 
the final weight. 
N = 138 patients 
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    P – Value = 00.00 
 
Group ( A ) the intermittent regimen group EMP\R\INH\PZA  for 2 
months then R\ INH twice weekly for 4  months .       
Group ( B )  the short course daily regimen group S\R\INH\PZA for2 
months then R\ INH once daily for 4 months .                     
 
 
Table (3.16): Percentage of patients cured 
 
N = 275 patients 
 
 
 
Group A Group B 
Total 
 
No % No % No % 
 65
Cured 71 55.5% 67 45.6% 138 50.2% 
 
Not cured  57 44.5% 80 54.4% 137 49.8% 
Total 128 100.0% 147 100.0% 275 100.0% 
 
Chi-Square Tests  
 
 Value P-Value
Pearson Chi-Square 2.677 0.102 
 
 
 
Cured means sputum completed treatment negative 
 
Group ( A ) the intermittent regimen group EMP\R\INH\PZA  for 2 
months then R\ INH twice weekly for 4  months .       
Group ( B )  the short course daily regimen group S\R\INH\PZA for2 
months then R\ INH once daily for 4 months .                          
 
 
 
 
 
 
 
 
 
 
Figure (3.14): Adherence to treatment in relation to time 
 
N = 128 patients 
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P-value = 0.097 
Group ( A ) the intermittent regimen group EMP\R\INH\PZA  for 2 
months then R\ INH twice weekly for 4  months .       
Group ( B )  the short course daily regimen group S\R\INH\PZA for2 
months then R\ INH once daily for 4 months . 
 
 
 
 
Table (3.17)     Relapse rate 
N = 138 patients 
 
 
 Group A  Group B 
Duration of Number of % Positive  Number of % Positive 
 67
follow up patients sputum patients sputum 
> 6 month   
 
       28 39.4 0       19 28.4 0 
6 – 12 month        13 18.3 0       14 20.9 0 
12 – 18 month         18 25.3 0        9 13.4 0 
Not come for 
follow up 
       12 17        25 37.3  
Total         71 100 %        67 100 %  
 
 
 
Group ( A ) the intermittent regimen group EMP\R\INH\PZA  for 2 
months then R\ INH twice weekly for 4  months .       
Group ( B )  the short course daily regimen group S\R\INH\PZA for2 
months then R\ INH once daily for 4 months . 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure (3.15) Patient Satisfaction 
                                            N = 138 patients 
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Group ( A ) the intermittent regimen group EMP\R\INH\PZA  for 2 
months then R\ INH twice weekly for 4  months .       
Group ( B )  the short course daily regimen group S\R\INH\PZA for2 
months then R\ INH once daily for 4 months .                            
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Table (3.18) Comparing the means of Alanine Aminotransferase 
(ALT) among tuberculous patients at different levels 
during the course treatment 
N = 138 patients 
 
 
 GROUP N Mean p- value 
Group A 71 28.179
Initial ALT  
Group B 67 22.496
  0.175 
Group A 71 25.135
ALT after 2 month
Group B 67 21.631
0.349 
Group A 71 20.900
ALT after 4 month
Group B 67 19.567
0.688 
 
 
 
 
Normal value >35 units \ liter 
 
Group ( A ) the intermittent regimen group EMP\R\INH\PZA  for 2 
months then R\ INH twice weekly for 4  months .      
 Group ( B )the short course daily regimen group S\R\INH\PZA  for2 
months then R\ INH once daily for 4 months . 
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Table (3.19)  Comparing the means of Aspartate Aminotransferase 
(AST)among tuberculous patients at different levels 
during the course treatment 
 
 
 
 
 
 
 
Normal value >35 units \ liter 
  
 Group ( A ) the intermittent regimen group E\R\H\Z  for 2 months then 
R\ Z twice weekly for 4  months .           
Group ( B )  the short course daily regimen group S\R\H\Z for2 months 
then R\ Z once daily for 4 months . 
 
 
 GROUP N Mean p- value 
Group A 71 42.765
Initial AST 
Group B 67 37.590
0-298 
Group A 71 29.677
AST after 2 month
Group B 67 28.522
0.746 
Group A 71 26.639
AST after 4 month
Group B 67 27.069
0.913 
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Table (3.20)            The means of ALT for Group A 
 
                                N = 71 patients 
 
 Mean SIg.(2-tailed) 
ALT(Initial) 28.179 
ALT(2 month) 25.135 
0.501 
 
ALT(Initial) 28.179 
ALT(4 month) 20.900 
0.024 
ALT(2 month) 25.135 
ALT(4 month) 20.900 
0.219 
 
 
Table (3.21)        The means of ALT for Group B 
 
                            N = 67 patients 
 
 Mean SIg.(2-tailed) 
ALT(Initial) 22.496 
ALT(2 month) 21.631 
0.586 
 
ALT(Initial) 22.496 
ALT(4 month) 19.567 
0.132 
ALT(2 month) 21.631 
ALT(4 month) 19.567 
0.217 
 
Normal value > 35 units \ liter  
 
Group ( A ) the intermittent regimen group EMP\R\INH\PZA  for 2 
months then R\ INH twice weekly for 4  months .       
Group ( B )  the short course daily regimen group S\R\INH\PZA for2 
months then R\ INH once daily for 4 months .                      
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Table (3.22)            The means of AST for Group A: 
 
                                N = 71 patients 
 
 Mean SIg.(2-tailed) 
Initial AST 42.765 
AST(2 month) 29.677 
0.001 
 
Initial AST 42.765 
AST(4 month) 26.639 
0.000 
AST(2 month) 29.677 
AST(4 month) 26.639 
0.350 
 
 
Table (3.23)           The  means of AST for Group B: 
 
                               N = 67 patients 
 
 Mean SIg.(2-tailed) 
Initial AST 22.496 
AST(2 month) 21.631 
0.005 
 
Initial AST 22.496 
AST(4 month) 19.567 
0.008 
AST(2 month) 21.631 
AST(4 month) 19.567 
0.497 
 
 
 
Normal value >35 units \ liter  
  
Group ( A ) the intermittent regimen group EMP\R\INH\PZA  for 2 
months then R\ INH twice weekly for 4  months .       
Group ( B )  the short course daily regimen group S\R\INH\PZA for2 
months then R\ INH once daily for 4 months . 
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Table (3.24)  The percentage of elevated ALT among Tuberculous 
patients 
N = 138 patients 
 
GROUP Pearson Chi-Square 
Group A Group B 
Total 
 
 
 
            ALT 
No % No % No % 
Value P-Value 
Normal 56 78.9% 58 86.6% 114 82.6% 
initial ALT 
Elevated  15 21.1% 9 13.4% 24 17.4% 
1.420 .233 
Normal 57 80.3% 58 86.6% 115 83.3% ALT after 2 
months Elevated 14 19.7% 9 13.4% 23 16.7% 
.981 .322 
Normal 62 87.3% 60 89.6% 122 88.4% ALT after 
4months Elevated 9 12.7% 7 10.4% 16 11.6% 
.167 .683 
 
 
 
Normal value > 35 units \ liter  
 
Group ( A ) the intermittent regimen group EMP\R\INH\PZA  for 2 
months then R\ INH twice weekly for 4  months .       
Group ( B )  the short course daily regimen group S\R\INH\PZA for2 
months then R\ INH once daily for 4 months .                                        
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Table (3.25)  The percentage of elevated AST among tuberculous 
patients                  
N = 138 patients 
 
 
GROUP Pearson  Chi-Square 
Group A Group B 
Total 
 
 
      
             AST No % No % No % 
Value P-Value 
Normal 33 46.5% 41 61.2% 74 53.6% 
Initial AST 
Elevated  38 53.5% 26 38.8% 64 46.4% 
3.001 .083 
Normal 51 71.8% 47 70.1% 98 71.0% AST after 2 
months Elevated  20 28.2% 20 29.9% 40 29.0% 
.047 .828 
Normal 60 84.5% 49 73.1% 109 79.0% AST after 4 
months Elevated  11 15.5% 18 26.9% 29 21.0% 
2.686 .101 
 
 
 
Treatment discontinuation due to Rifampcin induced jaundice and 
hypersensitivity was deselected in   .7 % ( 1 patient ) in group B , the 
patient was excluded although  she  was recovered after rifampcin was 
stopped . 
 
Drug- induced jaundice occurred in 1, 4%of the patients in group A and 
3% in groupB.   
 
Normal value > 35 units \ liter  
 
Group ( A ) the intermittent regimen group EMP\R\INH\PZA  for 2 
months then R\ INH twice weekly for 4  months .       
Group ( B )  the short course daily regimen group S\R\INH\PZA for2 
months then R\ INH once daily for 4 months .    
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Table (3.26) Peripheral neuropathy reported among tuberculous 
patients during the course of treatment 
N = 138 patients 
 
 
 
GROUP Pearson  Chi-Square 
Group A Group B 
Total 
 
No % No % No % 
Value P-Value 
Yes 40 56.3% 38 56.7% 78 56.5% After 2 
wks No 31 43.7% 29 43.3% 60 43.5% 
.002 .964 
Yes 38 53.5% 42 62.7% 80 58.0% After 2 
months No 33 46.5% 25 37.3% 58 42.0% 
1.189 .276 
Yes 40 56.3% 35 52.2% 75 54.3% After 6 
months No 31 43.7% 32 47.8% 63 45.7% 
.233 .629 
 
 
 
 
Group ( A ) the intermittent regimen group EMP\R\INH\PZA  for 2 
months then R\ INH twice weekly for 4  months .       
Group ( B )  the short course daily regimen group S\R\INH\PZA for2 
months then R\ INH once daily for 4 months . 
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Table (3.27)  Gastrointestinal disturbances reported among        
tuberculous patients during the course of treatment. 
N = 138 patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Group ( A ) the intermittent regimen group EMP\R\INH\PZA  for 2 months then R\ INH twice weekly for 4  
months .       
Group ( B )  the short course daily regimen group S\R\INH\PZA for2 months then R\ INH once daily for 4 months 
. 
 
Nausea 
Group A Group B 
 
No % No % P-Value 
Yes 24 33.8% 33 49.3% After 2 
weeks No 47 66.2% 34 50.7% 
.065 
Yes 21 29.6% 32 47.8% After 2 
months No 50 70.4% 35 52.2% 
.028 
Yes 14 19.7% 24 35.8% After 6 
months No 57 80.3% 43 64.2% 
.034 
Vomiting  
Group A Group B 
  No % No % 
P-Value 
After 2 
weeks Yes 9 12.7% 12 17.9% 
 No 62 87.3% 55 82.1% 
.392 
After 2 
months Yes 5 7.0% 5 7.5% 
 No 66 93.0% 62 92.5% 
.924 
After 6 
months Yes 3 4.2% 2 3.0% 
 No 68 95.8% 65 97.0% 
.697 
Other GIT disturbances 
Group A Group B 
 
No % No % P-Value 
Yes 14 19.7% 9 13.4% After 2 
weeks No 57 80.3% 58 86.6% 
.322 
After 2 
months Yes 9 12.7% 9 13.4% 
 No 62 87.3% 58 86.6% 
.895 
Yes 4 5.6% 4 6.0% After 6 
months No 67 94.4% 63 94.0% 
.933 
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Table (3.28) Abdominal pain reported among tuberculous patients 
during the course of treatment 
N = 138 patients 
 
 
GROUP Pearson  Chi-Square 
Group A Group B 
Total 
 
No % No % No % 
Value P-Value 
Yes 6 8.5% 12 17.9% 18 13.0% 
After 2 wks 
No 65 91.5% 55 82.1% 120 87.0% 
2.720 .099 
Yes 7 9.9% 12 17.9% 19 13.8% After 2 
months No 64 90.1% 55 82.1% 119 86.2% 
1.882 .170 
Yes 6 8.5% 2 3.0% 8 5.8% After 6 
months No 65 91.5% 65 97.0% 130 94.2% 
1.886 .170 
 
 
 
 
 
 
Group ( A ) the intermittent regimen group EMP\R\INH\PZA  for 2 
months then R\ INH twice weekly for 4  months .       
Group ( B )  the short course daily regimen group S\R\INH\PZA for2 
months then R\ INH once daily for 4 months .               
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Table (3.39)     Itching reported among tuberculous patients during 
the course of treatment 
 
N = 138 patients 
 
GROUP Pearson Chi-Square 
Group A Group B 
Total 
 
No % No % No % 
Value P-Value 
Yes 15 21.1% 16 23.9% 31 22.5% 
After 2 wks 
No 56 78.9% 51 76.1% 107 77.5% 
.150 .698 
Yes 9 12.7% 12 17.9% 21 15.2% After 2 
months No 62 87.3% 55 82.1% 117 84.8% 
.732 .392 
Yes 2 2.8% 4 6.0% 6 4.3% After 6 
months No 69 97.2% 63 94.0% 132 95.7% 
.824 .364 
 
 
Group ( A ) the intermittent regimen group EMP\R\INH\PZA  for 2 
months then R\ INH twice weekly for 4  months .       
Group ( B )  the short course daily regimen group S\R\INH\PZA for2 
months then R\ INH once daily for 4 months .s                  
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Table (3.30) Arthritis reported among tuberculous patients during 
the course of treatment 
 
N = 138 patients 
 
 
GROUP Pearson  Chi-Square 
Group A Group B 
Total 
 
No % No % No % 
Value P-Value 
Yes 27 38.0% 20 29.9% 47 34.1% After 2 
wks No 44 62.0% 47 70.1% 91 65.9% 
1.026 .311 
Yes 33 46.5% 22 32.8% 55 39.9% After 2 
months No 38 53.5% 45 67.2% 83 60.1% 
2.677 .102 
Yes 23 32.4% 22 32.8% 45 32.6% After 6 
months No 48 67.6% 45 67.2% 93 67.4% 
.003 .956 
 
 
 
Group ( A ) the intermittent regimen group EMP\R\INH\PZA  for 2 
months then R\ INH twice weekly for 4  months .       
Group ( B )  the short course daily regimen group S\R\INH\PZA for2 
months then R\ INH once daily for 4 months .                    
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Figure (3.16) Treatment outcome in group A and B 
 
N = 275 patients 
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Group ( A ) the intermittent regimen group EMP\R\INH\PZA  for 2 
months then R\ INH twice weekly for 4  months .       
Group ( B )  the short course daily regimen group S\R\INH\PZA for2 
months then R\ INH once daily for 4 months . 
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4. DISCUSSION 
 
4.1 Discussion and conclusion 
As far as can be ascertained a randomized clinical  trial addressing the 
intermittent chemotherapy has not been conducted yet in Sudan , 
according to Elkheir 2005, the intermittent regimens may be more 
suitable in Sudan , therefore, a study  to assess the efficacy of  
intermittent chemotherapy  and the adverse drug reactions of the 
antituberculous drugs is justifiable and highly needed , Putting in mind 
the increasing incidence rate of T.B in the  Sudan generally and specially 
in the White Nile area. 
This study was carried out at Kosti teaching hospital , the major referral 
hospital in the state , to evaluate the efficacy of intermittent 
chemotherapy in regards to microbiological , radiological clinical success 
rate ,defaulter rate , adverse drug reactions including hepatotoxicty, 
relapse rate and patient satisfaction, in addition to comparing intermittent 
drug therapy with the conventional adopted short course chemotherapy 
(S.C.C.) not only this but also to determine the prevalence of tuberculosis 
among age and sex groups and determination of the prevalence of 
smoking among tuberculous patients.                                                                             
Directly observed treatment short course strategy (DOTS) with closed 
supervision every two weeks was applied.  
 A descriptive and comparative designs were used, ( 275 patients ) were 
enrolled in the study where 55 % of them   were males and 45 % were 
females , these results are not much different from other studies stated by  
Mohammed and coworker 2007 in South Africa   56 % females , 44% 
males respectively and nearly similar to the results obtained by  Muhan 
and coworker 2007  in Pakistan 54 males and 46 females also when the 
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prevalence is compared to previous studies conducted in Sudan using 
Gender as an indicator it is  different from the results stated by ( Zaki 
1995 ) 60% males and 40 % females and   ( Elkheir 2005 ) 63 % males 
and 37 % females , in general the Sudan National  T B Programme   
stated that  the  number of the infected males  and females is nearly equal  
( Ali L.. et al 2007 ) . 
Most of Tuberculous patients are young i.e. 63% of males and 72.5% of 
female were < 45 years age (figure 3.1) shows sex and age distribution. 
Considering the educational level , it was found that about 59 % of the 
entered patients were illiterate, which is  higher than the percentage 
mentioned by Sudan National  T B Programme   27.3 %  were illiterate in 
Khartoum state ( Ali L. et al 2007 )  , this alarming  situation reflects the 
problem of TB in  the White Nile state and  the educational levels 
between Khartoum as a capital and the White Nile. Generally it is known 
that the TB infection rate is inversely proportional to the educational level 
(figure 3.2).  
   The study revealed that 29 % of the males were cigarette smokers and 
7.9 % of them were Shisha (water pipe) smokers(figure 3.3 and 3.4), this 
type of smoking assists in TB infection transmission due to the use of one 
pipe by more than one smoker in the public cafés and clubs, smoking is 
higher in males and female are usually nonsmokers due cultural reasons, 
In Karachi University students were unaware of the fact that shisha, or 
water-pipe smoking, is just as harmful as cigarette smoking (Faiza Ilyas 
2008 ).  
A comparative study was conducted to compare the results of the 
two regimens 71 patients out of 128 completed the treatment by  
intermittent regimen (group A ) and 67 patients out of 147 cured by  daily 
regimen (group B) , complete conversion from positive to negative by the 
end of the first month occurred  in all patients of group B , while    ( 2 
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cases ) in group remained positive after the end of the first month , 
however, 97.2 %of the patients converted to negative, it was observed 
that ( 2 cases ) by the end of the second month in group B remained 
positive, unfortunately one of these two cases defaulted the treatment  . 
This can be explained either by false negative by the end of the first 
month or emergence of new positive strains, whatever the cause, one of 
these patients defaulted and the other converted to smear negative by the 
end of the third month and remained negative through her follow up. By 
the end of the fourth, fifth and the sixth month, no patient with positive 
sputum in the two groups, the differences were insignificant (table 3.1). 
Concerning the radiological findings it was found that  31% of the films 
were normal X-Ray which is higher than the situation in USA stated by  
Pepper  and coworker 2008 who mentioned that normal chest X-Ray 
among patients with culture-confirmed pulmonary TB was 13% , the 
inconsistency of these results and the and the situation in USA is due to 
the high sensitivity of culture and the difference of the culture-confirmed 
diagnostic facilities between Sudan and USA. Bronchiectesis was not 
detected in this study even in patients followed up for 18 months after 
completion their regimen, which is different from 7% bronchiectesis 
found in Jordan by El-Khushman  and coworker 2006 ( see table (3.2).  
High percentage of far advanced lesion was detected among X-Ray films 
compared to minimal lesion 22.5% to 16.6% respectively; this indicates 
that the patients in the study area are late comers (figure 3.5).  
The right lung was involved in 20.4 % of cases , the left lung in 14.2% 
and bilateral lung involvement was noted in 34.5% of patients , the 
percentage of lesion in the upper zones were 5.9 on the right lung , 20.5 
%  on the left lung and only 1 %  bilaterally ,  these results differ from the 
situation in Jordan stated by El-Khushman  and coworker 2006 who 
found that, the right lung was involved in 51% of cases , the left lung in 
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27% , bilateral lung involvement was  22% of patients and the upper 
lobes were involved in 63% figure (3.6) . 
Concerning the progress of minimal lesion significantly high percentage 
was improved to normal X-Ray 58%  in group A and 53 %  in group B , 
42 %  in group A and 40 %  in group B remained as minimal lesion  
figure (3.7).  
progress of moderate lesion  result revealed that 14.3 % of the films were 
been improved to normal  in the intermittent group and  14.3 %  of the 
films converted to minimal lesion   and 72 % of the  moderate lesion were 
no changed the intermittent group  while in the daily group 100 %  still 
moderate lesion figure (3.8). 
The results of moderately advanced lesion revealed that both regimen 
cause an improvement of 17 % of this these types of lesion to normal X-
Ray, 28 % in the intermittent group  and 33 % in  the daily group were 
converted to minimal lesion , 22 % of the intermittent group were 
converted to moderate lesion  , 33% and 50 %  of the intermittent and the 
daily group successively were not changed  (3.9). 
The results of far advanced lesion revealed that intermittent  regimen 
improved 16.6%  of the films to normal and minimal lesion , 8.3 % 
improved to moderate lesion , 33.3 %  to moderately advanced lesion and 
25 % remained unchanged , while in the daily regimen , 21 % were 
improved to normal  and minimal lesion , 5.2 % to  moderate lesion, 27 % 
to moderately advanced lesion and 27.6 % remained unchanged the  
statistical analysis revealed a significant difference between the two 
groups (figure 3.10). 
The study revealed high percentage of productive cough compared to dry 
cough (figure 3.11), night fever was detected in high percentage of 
patients (table 3.6) the differences were statistically insignificant. 
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Significantly high percentage of the patients complain of sweating 67.4%, 
loss of appetite 77.5%, chest pain 76.8% and haemoptysis in 70.3% . 
The initial symptoms were monitored at a short level (2 weeks), 
intermediate level (2 months), and long level (6 months), no significant 
difference between the two regimens in complete disappearance of cough 
after 2weeks 48.6 % in group A and 30.3 % in group B, but group B 
shows a significantly high percentage of partial improvement of cough 
after 2 months and 6 months (table 3.6). 
The two regimens are equivalent in complete improvement of fever 
after 2 weeks, but group B show an insignificant high percentage of 
partial improvement of fever and sweat after 2 months and 6 months 
(table 3.9). Complete improvement of sweating was insignificantly high 
in group A (table 3.10) 
No significant difference between the two regimens in complete or partial 
improvement of loosing appetite  after 2 weeks , 2 months and 6 months ( 
table 3.12) . 
By the end of the treatment, group A revealed a significant high 
percentage of complete improvement of chest pain, while Group B 
revealed a significant high percentage of partial improvement of the same 
symptom (table 3.13) .Complete disappearance of haemoptysis was 
detected in the two groups (table 3.15).  
The study revealed that the intermittent regimen is effective in 
complete disappearance of cough and fever and the daily regimen is 
effective in partial improvement of the same symptoms (tables 3.5 3.7). 
In spite of these facts, however, we cannot rely only on the regimen as a 
solo (single) in the clinical improvement, no doubt other factors that are 
not monitored should be considered, in spite of the effect of the same 
factor in the initial condition of the patient.  
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Significant decrease in the means of ESR after 6 month compared 
to the initial results in the two groups from 110.3 to 36 in group A and 
105.6 to 35.6 in group B figure (3.12). 
Significant weight gain was detected in the two groups, which is 
confirmed by the increase in the means of weights from 48.6 kg to 53 kg 
in group A and 50.6 kg to 55.3 kg in group B, patient adherence and 
regular food supply may assist in weight gain figure (3.13).  
      Default rate was lower in group A , it was found that ( 71 out of 128 
patients ) 55.5 % of the patients were cured , while only ( 67 out of 147 
patients ) 46.5 % of group B cured , it is known that patients adherence is 
inversely proportional to many factors one of them is  the dosing 
frequency , the difference was statistically nonsignificant ( table 3.16) , it 
was found that default rate  was higher than that stated in China by 
Quing-Song Bao and coworker 2007 5.9 % , in South Africa  by 
Wilkinson D., 1994 who found that  89 % of the surviving patient were 
cured  and in Khartoum 42.9% defaulted   Sharaf-Edin and coworker 
2000 .  
One of the philosophies of giving short course therapy is to minimize the 
defaulter rate, moreover intermittent regimen was formulated and advised 
to induce acceptability and adherence of the patients to their prescribed 
regimen , although the enrolled patients gain free medicines , laboratory 
investigations, X-Ray, proper follow up and medical consultancy in 
addition to food supplies , the defaulter rate was still high this may be 
explained by the influence of socioeconomic factors including stigma, 
psychological factor or the sense of well-being after starting the treatment 
.   
It was found that the default rate was higher in the two groups in 
the first two months of the treatment ( 15.8 % in group A and 12.8 % in 
group B for the first month and 11 % in group A and 20.4 % in group B 
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for the second month ) when these results were compared to the  results 
of the last two months of the treatment  fourth ( 3.9 % for group A and 
6.8 % for group B ) and the fifth months  ( 3.1 % for group A  and 2 % 
for group B ) , furthermore , in the first two months , the default rate was 
lower in group A than that in group B  (figure 3.14) ,  this may be due to 
the fact that the initial phase of the treatment in the daily regimen ( group 
B ) was started using  streptomycin injection , which is tedious and 
intolerable to the patients or may be due  to a psychological factor due to 
the daily intake of treatment , it is known that even if the patient was 
given a chocolate daily for six months , it will become tedious and one 
can expect some sort of interruption or defaulting. 
Concerning the relapse rate, it was assessed by 
clinicobacteriological (sputum for Alcohol Acid Fast Bacilli) 
measurement, after 6, 12 and 18 months, 39.4%of the patients whowere 
cured the by the intermittent regimen were followed up to trace the 
relapse rate after 6 months. 18.3 % after 6-12 months and 25.3 % after 
12- 18 months successively and 28.4 % of the patient who were cured by 
the daily regimen were followed up 6 months. 20.9 % for 6-12 months 
and 13.4 % for 12- 18 months successively,   fortunately no relapse case 
i.e. sputum positive was detected in the two groups(table 3.17), which is 
different from the findings of previous study conducted in Indonesia by 
Suryinto and coworker 2008 who found that the relapse rate was 10.1%.  
Assessment of patients satisfaction was done using questionnaire 
annex(8), this revealed that high percentage of the patients 87.3 % in 
group A were satisfied by the intermittent regimen , while in group B , 
only 38.8 % of the patients mentioned that they were satisfied by the 
daily regimen (figure 3.15), this low percentage was expected because it 
is known that taking drugs daily is an intolerable process , not only this , 
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but also the patients in group B were exposed to intramuscular 
streptomycin for the first two months of the course which is painful. 
Comparing the initial means of both Alanineamino transferase 
(ALT) and Aspartate aminotransferase (AST) enzymes with the result of 
the same liver enzymes after two and four months reduction of the initial 
ALT was detected 28.2 to 25.1 and 21 in group A and 22.5 to 21.6 and 
19.6 in group B respectively within the normal values (<35 units\liter), 
the differences were statistically insignificant (table 3.18). 
An elevated initial mean of AST was detected in the two groups 
(more than 35units\liter) which was decreased after 2 and 4 months of 
treatment from 42.8 to 29.7 and 26.7 in group A and from 37.6 to 28.5 
and 27.1 in group B respectively the differences were statistically 
insignificant (table 3.19), technical error is excluded due to proper 
procedure and highly advanced Spectrophotometer , therefore , this 
elevation can be referred to the injury and cell damage of lungs cause by 
TB infection which can be matched by the fact stated by ( Frances and 
Marshall 2004) AST is released in circulation following the cell injury or 
death in the organs of high metabolic activity the heart, liver, skeletal 
muscles, brain, kidney, pancreas and lung, this can be supported by the 
observed reduction of the enzyme levels after starting the treatment. 
Comparing the results of initial liver enzymes within the group 
after 2 and 4 month study revealed decreased initial ALT in group A, 
from 28.2 initially to 25.1 after 2month, from 28.2 initially to 21 after 4 
month and from 25.1 to 21 after 4 month and it decreased in group B 
from 22.5 to 21.6, 22.5 to 19.6 and 21.6 to 19.6 respectively within the 
normal values (<35 units\liter), (table3.20 and 3.21). 
The two regimens significantly reduce the initial AST when it is 
compared with that after 2 and 4 months from 42.8 to 29.7 and 26.7 in 
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group A and from 22.5 to 21.6 and 19.6 in group B respectively (table 
3.22 and 3.23).  
The percentage of patients with initial elevated ALT and AST after 
2 and 4 months decreased in the two groups. For ALT from 21.1 % to 
19.7 % and 12.7 % in group A and from 13.4% initially and after 
2months to 10.4% after 4months in group B. for AST from 53.5% to 
28.2% and 15.5% in group A and from 38.8% initially to 30% and 27% 
respectively the differences were statistically insignificant.t table (3.24 
and 3.25).     
Treatment discontinuation due to hepatitis as a result of rifampcin 
hypersensitivity was detected in  0 .7 % (1 patient) in group B, the patient 
was excluded although she was recovered after rifampcin was stopped. 
 Drug- induced jaundice occurred in 1, 4%of the patients in group 
A and 3% in group but,  these patients recovered after stopping the 
treatment for a week then treatment continued without any problem . 
         As it is known that the main adverse drug reactions of INH 
due to it is competition with pyridoxine are peripheral neuritis, nausea 
and vomiting, the study revealed that the incidence of nausea is 
significantly high in the daily regimen group than in the intermittent 
regimen group after 2 month and 6 month , this may be due to high doses 
of INH taken by the daily regimen group compared to the dose taken by 
the intermittent group, however James and coworker 1996 mentioned that 
Eskimos, Japanese, Chinese are predominantly fast acetylators whereas 
Caucasian, Negroes and Indians are slow acetylators. Daily 
administration of INH may lead to  accumulative toxicity this hypothesis 
is supported by insignificant difference between the two groups at the 
short level ( 2 weeks ) , see table (3.26).  
No significant difference in development of peripheral neuritis, 
vomiting, GIT disturbances, abdominal pain, runny nose, visual 
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disturbances, urticaria, arthropathy, and back pain between the two 
groups.  
Concerning  serious adverse drug reactions ,  Flu like syndrome 
was not identified which  usually limits the use of Rifampcin dependant 
intermittent regimen and many investigators describe the syndrome , 
according  to Rajinder Singh Bedi and coworker 2000 in India the flu 
syndrome has usually been associated with intermittent (rarely daily) use 
of Rifampicin, though a case of Ethambutol-induced. Flu like syndrome 
was been identified, and 3 cases of flu like symptoms due to Isoniazid 
were found in 1989.  The findings are also different from the fact stated 
by James and coworker 1996) that flu like is a common adverse drug 
reaction of rifampcin dependant regimen also different from Gerald K. 
Mc Evoy and coworker 1988  who mentioned that Flu like syndrome was 
been associated with the use of twice a week intermittent rifampcin and 
identified in 1% of the patients (tables 3.26 to 3.30) show the adverse 
drug reactions.                                                                          
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4.2 Conclusion  
- 162 patients (59 %) of the patients were illiterate. 
- The study revealed that cigarette smoking was detected among 29% and 
7.9%were shisha smokers. 
-The twice weekly 6 month intermittent is effective as the daily regimen 
more preferred by the vast majority of patients exposed to this regimen 
and less expensive than the daily 6 month regimen. 
-Complete conversion of sputum from positive to negative by the end of 
the first month occurred in group B, while in 2.8 % in group A it was 
still positive and by the end of the second month the sputum was 
completely converted to negative in group A while in 3 % of group B it 
was still positive. Complete conversion in the two groups occurred 
after the end of third month. 
- Delay in case identification was observed and it may be due to patients 
faults in the study. 
- Conversion of minimal lesions to normal X-Ray was significantly 
higher in the intermittent group 58% VS 53 % in the daily group and 
the conversion of far advanced lesions to normal was significantly 
higher in the daily regimen 21 % VS16.6% in the intermittent group.  
-  Improvement of clinical symptoms occurred in both group A and B. 
- Significant decrease in the means of ESR after 6 month compared to the 
initial results in the two groups from 110.3 to 36 in group A and 105.6 
to 35.6 in group B. 
Significant weight gain was detected in the two groups, which is 
confirmed by the increase in the means of weights from 48.6 kg to 53 
kg in group A and 50.6 kg to 55.3 kg in group B. 
- Significant initial elevated means of AST was detected in the two 
groups which was  significantly decreased in the intermittent regimen 
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after 2 and 4 months, the decrease was significant only after 2month in 
the daily group and  Significant decrease in the percentage of patients 
with initial elevated ALT and AST in the two groups after 2 and 4 
months. 
- No relapse case detected in the two groups and death rate was 
comparable in the two regimens.  
-There was no significant different between the intermittent and the daily 
regimen concerning the microbiological outcome, the radiological 
progress and the clinical improvement. Symptoms of tuberculosis 
started to be significantly improved immediately after the completion 
of 2 weeks in the initial phase, the adverse drug reactions were 
tolerable concerning the majority of the patients completing the course 
of the treatment, but the intermittent regimen was found to be superior 
when the financial issue and patient satisfaction were considered.   
-Ultimately the intermittent regimen reduced about 43 % of the cost of 
drugs consumed in the continuation phase of TB treatment compared to 
the daily regimen (12 tablets\week) VS (21 tablets \week) successively. 
-  Patients are strongly involved in Tuberculosis therapeutic failure due 
their poor adherence which is indicated by the high default rate 
although , they were supplied by free antituberculous drug , food 
supplies , in addition to free laboratory , and X-Ray investigations and 
specialist consultancy during the study. 
Treatment outcome was summarized in figure (3.16), the cure rate was 
higher in group A than group B 55. % to 45.5 %, defaulter rate was lower 
in group A than group 40.6% to 51%, the percentage of died patient was 
comparable in group A 0.8% to 0.7% in group B, no relapse case detected 
in the two groups. 
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4.3 Recommendations 
1. Implementation of twice weekly intermittent regimen started with 
ethambutol tablets instead of streptomycin for treatment of TB in 
Sudan will reduce the cost and will enhance patient adherence. 
2. Patient adherence should be strongly supported by designing and 
application of educational interventions to minimize defaulter rate.  
3. The risk of TB transmission through Shisha smoking should be clearly 
explained to the smokers and the worker of the public cafes, clubs and 
those who smoke in groups  
4. Pyridoxine is better to be added routinely as an adjuvant for TB 
treatment to reduce peripheral neuropathy, nausea and vomiting 
associated with isoniazid ,  
5. High need of the raising of community and decision makers awareness 
to attract their attention and efforts to stop the danger of TB. 
6. Strategies to strengthening early case finding and diagnosis must be 
designed and implemented. 
7.Furthure studies to clarify the actual cause of the initial liver enzyme 
elevation and genetic map to determine the rate of INH acetylation in 
Sudanese patients are highly needed.  
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Annexes 
Annex1 
 The minimum sample size in relation to the community of the study . 
 
Community 
of study 
Sample 
size 
Community 
of study 
Sample 
size 
Community 
of study 
Sample 
size 
10 10 220 140 1200 291 
15 14 230 144 1300 297 
20 19 240 148 1400 302 
25 24 250 152 1500 306 
30 28 260 155 1600 310 
35 30 270 159 1700 313 
40 36 280 162 1800 317 
45 40 290 165 1900 320 
50 44 300 159 2000 322 
55 48 320 175 2200 327 
60 52 340 181 2400 313 
65 56 360 186 2600 335 
70 59 380 191 2800 338 
75 63 400 196 3000 341 
80 66 420 201 3500 346 
85 70 440 205 4000 351 
90 73 460 210 4500 354 
95 76 480 214 5000 357 
100 80 500 217 6000 361 
110 86 550 226 7000 364 
120 92 600 243 8000 367 
130 97 650 245 9000 368 
140 103 700 248 10000 370 
150 108 750 254 15000 375 
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160 113 800 260 20000 377 
170 118 850 265 30000 379 
180 123 900 269 40000 380 
190 127 950 274 50000 381 
200 132 1000 278 75000 382 
210 136 1100 285 100000 384 
 
Eldahian 2002 and Bayioumi 2006 
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Annex 3 
 
                              History taking and symptom registration form  
University of Khartoum Faculty of pharmacy department of pharmacology 
Date:………………….serial No:…………………………. 
Do you agree to be enrolled in this research: 
   Yes  No 
Name …………………………tribe………… 
Age…………………………Residence…………………………. 
 Distance from health center ……………..Km 
For haw long do you accommodate here……….year 
Do you have another Residence: 
yes   No 
Do you have another Occupation 
yes   No 
Monthly income…………………. SP     
Marital status: 
Married                 Single                  Divorced                Widow             
Educational level    
Illiterate                     Khalwa          Basic                Intermediate   
Secondary school                         University                    Postgraduate          Others  
Do you smoke:   Yes                           No   
How many cigarettes do you smoke/day…………For how long…..year 
Did you smoke before:   Yes                         No 
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When did you stop smoking………….month/year 
Have you got children: Yes                      No             how many 
Their ages 
1………………. ……..  2…………………… 
3……………………… 4……………………. 
5……………………… 6……………………. 
 
Any one of your family  
Yes                       No 
Anyone who take care about you: Yes                              No 
Relationship…………… 
Do you complain of : 
Cough               Dry                                Productive               For how long 
Fever               All the day                          Afternoon fever        Night fever 
For how long               Sweating                   Lost of appetite            Dyspnea 
Chest pain                      Spasm 
Color of sputum:  bloody                      greenish             white                      Others 
History  of diseases : 
Diabetes           Hypertension             Jaundice       schistosomiasis            recurrent 
malaria        leishmaniasis                  GITdisturbances   renal disturbances       heart 
diseases              others 
Do you use any drugs now     Yes                                 No 
If yes mention…………………………………………………. 
Can you come to the hospital daily to take your doses 
        Yes                                            No 
Mention the reason if you cannot………………………   
You must come and take your doses do you agree     Yes                       No 
Do you prefer to take your drug supply ?                          weekly          very two weeks     
Monthly     
Have you any problem to come to the hospital daily for to month? 
Yes                    No  
If yes mention the problem………………………… 
Do you know the complications of  defaulting the treatment? 
Yes                                       No 
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  ……………………………elpmaxe noitnem sey fI
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Annex 5 
 
Symptoms assessment form 
 
Percentage of improvement 
 100% 50% Others 
Fever    
Loss  of appetite    
Cough    
Chest pain    
Sweating    
Bloody sputum    
Others    
 
 
Your social status ? 
With your wife/husband?................................................................... 
Your work  ?........................................................................................ 
With the community?........................................................................... 
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 6 xennA
 
 smrof tnemssessa smotpmys fo ypoc detalsnart deifilpmiS
 
 :ﻣﻦ ﻣﺎ ﺑﺪﻳﺖ اﻟﻌﻼج ﻓﻰ ﺗﺤﺴﻦ 
 
 
  :ﺣﻴﺎﺗﻚ اﻻﺟﺘﻤﺎﻋﻴﺔ ﻣﺎﺷﺔ آﻴﻒ 
  : .............................................ﻣﻊ زوﺟﺘﻚ 
  : .............................................ﻣﻊ ﻋﻤﻠﻚ 
  .........................................: ..ﻣﻊ اﻟﻤﺠﺘﻤﻊ 
  
 ﻦ ﺑﻨﺴﺒﺔﺗﺤﺴ
 أﺧﺮى %05 %001 اﻟﺤﻤﻰ
    اﻟﺸﻬﻴﺔ
    اﻟﻜﺤﺔ
    أﻟﻢ اﻟﺼﺪر
    اﻟﻌﺮق
    ﺗﻔﺎف اﻟﺪم
    أﺧﺮى
 112
 
 
 
 
 
 
 
Annex 7 
 
Form of adverse drug reaction assessment 
Date................................ 
Name.......................................... 
Serial No.................................. 
After you start the treatment ,any adverse reactions developed ?  
Nausea                  Vomiting                 Dyspepsia                Abdominal 
pain 
Peripheral neuritis                   Recurrent rhinorhea               Jaundice  
Visual disturbances               urticaria            arthritis           back pain 
Others       . 
After you start the treatment ,do you feel improving ? 
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 8 xennA
 
 tnemssessa noitcaer gurd esreva fo mrof detalsnart deifilpmiS
 
  ﺑﺪﻳﺖ اﻟﻌﻼج ﻓﻰ أى ﻣﻀﺎﻋﻔﺎت ﺣﺼﻠﺖ ﻟﻴﻚ ﺑﻌﺪ 
  أﻟﻢ ﻓﻰ اﻟﺒﻄﻦ               ﺳﻮء هﻀﻢ     اﺳﺘﻔﺮاغ    ﻃﻤﺎم
  ﻳﺮﻗﺎن    رﺷﺢ ﻣﺴﺘﻤﺮ ﻣﺰﻋﺞ    ﺧﺪر ﻓﻰ اﻷﻃﺮاف
  أﻟﻢ ﻣﻔﺎﺻﻞ                            ﺣﻜﺔ    زﻏﻠﻠﻪ ﻓﻰ اﻟﻌﻴﻮن
  أﺧﺮى    أﻟﻢ ﻇﻬﺮ
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Annex 9 
 
Patient Satisfaction Assessment form 
 
 
   
Are you satisfied with the regimen you were treated by? 
 
 
No                                           Yes                                      
 115
   
 
 
 
Annex 10 
 
Simplified translated   Patient Satisfaction Assessment form 
 
   
ٍﺽﺍﺭ ﺕﻨﺃ لﻫ؟ﻪﺒ ﺕﺠﻟﻭﻋ ﻱﺫﻟﺍ ﻡﺎﻅﻨﻟﺍ ﻥﻋ  
  
  
                ﻻ                       ﻡﻌﻨ  
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Annex 11 
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